{
  "data": [
    {
      "ingredient2": "Digoxin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224830,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224831,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224832,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224833,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224838,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224839,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224840,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224842,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224843,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224844,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Pyridostigmine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224846,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224847,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224848,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224849,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224850,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224851,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224852,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224853,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224855,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224856,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224857,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224858,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224859,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224860,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224863,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224865,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224866,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224870,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224872,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Tretinoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224873,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224874,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224876,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Propofol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224878,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224879,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224881,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224882,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Risedronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224883,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224886,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224887,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224888,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224889,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224890,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224892,
      "ingredient1": "Azathioprine"
    },
    {
      "ingredient2": "Bictegravir",
      "severity": "Major",
      "effect": "INTERVAL: Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.",
      "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids. Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended. When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 43804,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Patiromer",
      "severity": "Major",
      "effect": "Systemic alkalosis has been reported when cation-exchange resins were administered orally in combination with nonabsorbable cation-donating preparations such as antacids or laxatives. The mechanism involves binding of the cation to the resin, which prevents the cation from neutralizing bicarbonate ions in the intestine and also interferes with the resin's potassium exchange capability.",
      "management_text": "Nonabsorbable calcium, magnesium, or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins. Alternatively, the interaction may be avoided by administering the resin as an enema.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106780,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Major",
      "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in plasma.",
      "management_text": "Concomitant use of selpercatinib with locally-acting antacids or other agents with acid neutralizing or reducing effects should generally be avoided. If coadministration is required, the manufacturer recommends taking selpercatinib 2 hours before or 2 hours after the antacid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 165232,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Erdafitinib",
      "severity": "Major",
      "effect": "Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib. Inhibition of the FGFR receptor has been shown to lead to an increase in serum phosphate levels.",
      "management_text": "The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178785,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dolutegravir",
      "severity": "Major",
      "effect": "INTERVAL: Coadministration with medications containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of dolutegravir. The mechanism of interaction has not been established.",
      "management_text": "Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations such as antacids, laxatives, or mineral supplements.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 135,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tolevamer",
      "severity": "Major",
      "effect": "Systemic alkalosis has been reported when cation-exchange resins were administered orally in combination with nonabsorbable cation-donating preparations such as antacids or laxatives. The mechanism involves binding of the cation to the resin, which prevents the cation from neutralizing bicarbonate ions in the intestine and also interferes with the resin's potassium exchange capability.",
      "management_text": "Nonabsorbable calcium, magnesium, or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins. Alternatively, the interaction may be avoided by administering the resin as an enema.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 111546,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Raltegravir",
      "severity": "Major",
      "effect": "Coadministration with aluminum-, magnesium-, and/or calcium-containing antacids may reduce the oral bioavailability of raltegravir. The proposed mechanism is chelation of raltegravir by polyvalent cations, but changes in solubility and lipophilicity of raltegravir related to pH increases may also contribute.",
      "management_text": "Concomitant use of raltegravir with aluminum- and/or magnesium-containing antacids should generally be avoided, even if administration is staggered. Antacids containing calcium carbonate should not be used with once-daily raltegravir (HD formulation), but may be used without dose adjustment for other raltegravir products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 159281,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Major",
      "effect": "Coadministration with drugs that elevate gastric pH such as H2-receptor antagonists and antacids may decrease the plasma concentrations of gefitinib.  According to the manufacturer, the solubility of gefitinib is pH-dependent and decreases sharply between pH 4 and 6, becoming practically insoluble above pH 7.",
      "management_text": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or antacids.  If concomitant treatment is required, the manufacturer recommends administering gefitinib 6 hours before or 6 hours after an H2-receptor antagonist or antacid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 291365,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Acalabrutinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of acalabrutinib and reduce its concentrations in plasma. The solubility of acalabrutinib is pH-dependent and decreases with increasing pH.",
      "management_text": "Concomitant use of acalabrutinib with proton pump inhibitors should generally be avoided. If acid suppression therapy is required, H2-receptor antagonists or antacids should be considered. The manufacturer recommends taking acalabrutinib 2 hours before H2-receptor antagonists and separating the dosing of antacids by at least 2 hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2895,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Baloxavir marboxil",
      "severity": "Moderate",
      "effect": "Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed mechanism is chelation of baloxavir by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "Concurrent administration of baloxavir marboxil with polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., aluminum, calcium, iron, magnesium, selenium, zinc) should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38520,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64926,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82224,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Delafloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82662,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Deutetrabenazine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84408,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98968,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Omadacycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105397,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Velpatasvir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of velpatasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with increased solubility at lower pH. Drugs that increase gastric pH are expected to decrease the plasma concentration of velpatasvir.",
      "management_text": "If an antacid is required, the antacid should be taken 4 hours before or 4 hours after administration of sofosbuvir-velpatasvir. The same precaution may be applicable to other drugs with antacid effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112023,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Neratinib",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of neratinib. The solubility of neratinib is pH-dependent and increases as neratinib becomes protonated at acidic pH, thus an increase in pH may interfere with its absorption.",
      "management_text": "Concomitant use of neratinib with drugs that increase gastric pH should generally be avoided. If acid-suppression therapy is required, short-acting antacids should be considered, with neratinib dosing separated by at least three hours after antacid administration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 143560,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Oliceridine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 147071,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Osilodrostat",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 148384,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Osimertinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 148606,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pitolisant",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155069,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ribociclib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 161236,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sarecycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 164278,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166302,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triclabendazole",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174094,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Valbenazine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175063,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178009,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fludeoxyglucose (18F)",
      "severity": "Moderate",
      "effect": "Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.",
      "management_text": "Clinicians should be aware of possible diagnostic interference associated with the following medications: colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181582,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fostemsavir",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184652,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185494,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185619,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ferrous fumarate",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190788,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ferrous sulfate anhydrous",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190826,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Relugolix",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190862,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cabotegravir",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids may decrease the bioavailability of oral cabotegravir. The proposed mechanism likely involves a pH-dependent reduction in dissolution and absorption of cabotegravir, which is poorly soluble over a wide pH range. The interaction has not been studied specifically with antacids.",
      "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of cabotegravir, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the oral cabotegravir dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192377,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Iron protein succinylate",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192384,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ozanimod",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 246531,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Polyethylene glycol (3350 with electrolytes)",
      "severity": "Moderate",
      "effect": "By increasing gastric pH, antacids may reduce the resistance of the enteric coating of bisacodyl tablets, resulting in earlier release of bisacodyl and gastric irritation and dyspepsia.",
      "management_text": "The administration of antacids and bisacodyl should be separated by at least one hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 258438,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 276598,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Phenyl salicylate",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 293999,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1479,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5953,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Acetazolamide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6328,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7908,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11301,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12201,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.",
      "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13996,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16274,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17166,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21042,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21630,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22070,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dextroamphetamine",
      "severity": "Moderate",
      "effect": "Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.",
      "management_text": "Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24397,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Amphetamine",
      "severity": "Moderate",
      "effect": "Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.",
      "management_text": "Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24485,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24828,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Propofol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25754,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31007,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Arsenic trioxide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31655,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Asenapine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 32875,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33929,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Atazanavir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of atazanavir and substantially reduce its concentrations in plasma. Atazanavir solubility decreases with increasing pH, thus reduction in gastric acidity may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.",
      "management_text": "Atazanavir should be administered 2 hours before or 1 hour after antacids or other oral agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34599,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Risedronic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.",
      "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34961,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Atomoxetine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35577,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Proguanil",
      "severity": "Moderate",
      "effect": "INTERVAL: The concomitant administration of magnesium trisilicate may significantly reduce the bioavailability of proguanil by reducing its absorption. Therapeutic failure may result. Other antacids and absorbent antidiarrheals may also interact with proguanil.",
      "management_text": "Antacids or antidiarrheals and proguanil should be taken at least 2 to 3 hours apart.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36000,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Atropine",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or adsorbent antidiarrheal agents may decrease the oral bioavailability of atropine.",
      "management_text": "Doses of antacids or adsorbent antidiarrheals should be separated from oral atropine by 3 to 4 hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36093,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Azithromycin",
      "severity": "Moderate",
      "effect": "INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids may reduce peak serum concentrations (Cmax) of oral azithromycin, but does not affect total absorption (AUC).",
      "management_text": "Azithromycin should be administered at least 1 hour before or 2 hours after antacids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 37839,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39285,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Benzphetamine",
      "severity": "Moderate",
      "effect": "Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.",
      "management_text": "Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41396,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41966,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43555,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bisacodyl",
      "severity": "Moderate",
      "effect": "INTERVAL: By increasing gastric pH, antacids may reduce the resistance of the enteric coating of bisacodyl tablets, resulting in earlier release of bisacodyl and gastric irritation and dyspepsia.",
      "management_text": "The administration of antacids and bisacodyl should be separated by at least one hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44580,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tetracycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44774,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Moderate",
      "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.",
      "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45816,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of agents that increase gastric pH such as H2-receptor antagonists or antacids may decrease the oral bioavailability of bosutinib and reduce its concentrations in plasma. The solubility of bosutinib decreases rapidly when the pH is above 5, resulting in reduced absorption.",
      "management_text": "To minimize the potential for interaction, H2-receptor antagonists or antacids should be administered at least 2 hours before or 2 hours after the bosutinib dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46657,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50707,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51174,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cabozantinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53168,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Calcifediol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53674,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53769,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 59312,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Moderate",
      "effect": "INTERVAL: Aluminum- or magnesium-containing antacids may interfere with the rate and extent of absorption of cefdinir. The mechanism has not been described but is most likely due to a chelation effect by the antacid or a change in intragastric pH.",
      "management_text": "If an antacid must be administered during cefdinir therapy, separate the times of administration by at least two hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60098,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cefditoren",
      "severity": "Moderate",
      "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60125,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cefpodoxime",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.",
      "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60305,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.",
      "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60506,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 61272,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Moderate",
      "effect": "INTERVAL: Concomitant administration of antacids or kaolin may reduce the oral bioavailability of chloroquine. The proposed mechanism is adsorption of chloroquine by polyvalent cations present in these agents. Delayed dissolution of chloroquine tablets in the presence of antacids may also be a contributing factor.",
      "management_text": "Chloroquine product labeling suggests separating the doses by at least 4 hours if concomitant therapy with antacids or kaolin is required. The same precaution may be applicable to hydroxychloroquine, although no data are available to support this recommendation. Some authorities recommend separating the dose of hydroxychloroquine from antacids and kaolin by at least 2 hours (AU).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63105,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Chlorothiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63449,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63778,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64107,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cholecalciferol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65149,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cilostazol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65334,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66150,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67008,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67913,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Clofazimine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70359,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 72394,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73981,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Corticotropin",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74746,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tetracosactide",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75163,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pancrelipase",
      "severity": "Moderate",
      "effect": "INTERVAL: By increasing gastric pH, antacids may reduce the resistance of the enteric coating of some formulations of pancreatic enzymes, resulting in earlier release and destruction of enzymatic activity.",
      "management_text": "The administration of antacids and enteric-coated pancreatic enzyme products should be separated by at least one hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75702,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75900,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.",
      "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77719,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of dasatinib.",
      "management_text": "Patients treated with dasatinib should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or paediatric oral solution) for at least two hours before and two hours after administration of dasatinib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80256,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Moderate",
      "effect": "INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use with foods, mineral supplements, or antacids that contain polyvalent cations has not been studied.",
      "management_text": "A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) or other polyvalent cations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81873,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Degarelix",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82445,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Moderate",
      "effect": "INTERVAL: Aluminum and magnesium containing antacids have been reported to decrease the bioavailability of delavirdine by an average of 41%. The mechanism may be related to decreased absorption of delavirdine. Other antacids may also interact.",
      "management_text": "Delavirdine administration should be separated by at least 1 hour from one of these preparations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82857,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Diclofenamide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85770,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Misoprostol",
      "severity": "Moderate",
      "effect": "Magnesium-containing antacids can exacerbate misoprostol-induced diarrhea. Additionally, antacids in general can reduce the bioavailability of misoprostol acid (the active metabolite of misoprostol), although clinical trials of misoprostol conducted with concomitant antacid use suggest that this effect is not clinically important.",
      "management_text": "Use of misoprostol in combination with magnesium-containing antacids is not recommended. If an antacid is needed, one that contains aluminum or calcium should be prescribed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 86055,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Methadone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 88345,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 88789,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 89752,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 89998,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Doxercalciferol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91830,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92592,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92967,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Minocycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 94768,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96041,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Eltrombopag",
      "severity": "Moderate",
      "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.",
      "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97687,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Elvitegravir",
      "severity": "Moderate",
      "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.",
      "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97876,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Rilpivirine",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids may decrease the oral bioavailability of rilpivirine. The proposed mechanism involves a pH-dependent reduction in dissolution and absorption of rilpivirine, which is poorly soluble over a wide pH range.",
      "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of rilpivirine, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the rilpivirine dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98453,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Thyroid, porcine",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of simethicone and/or antacid preparations may decrease the oral bioavailability of levothyroxine. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Additionally, because gastric acidity is required for adequate levothyroxine absorption, agents that effect intragastric pH may reduce levothyroxine absorption.",
      "management_text": "It is recommended to separate the times of administration of levothyroxine and simethicone and antacids or other antacid-containing preparations (e.g., didanosine buffered tablets or pediatric oral solution) by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 100266,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Methenamine",
      "severity": "Moderate",
      "effect": "Agents that can alkalinize the urine such as thiazide diuretics, carbonic anhydrase inhibitors, and antacids may decrease the antibacterial effectiveness of methenamine by inhibiting its conversion to formaldehyde. Methenamine is most effectively converted in an acidic milieu of pH less than 5.5.",
      "management_text": "Concomitant use of methenamine-containing preparations with thiazide diuretics, carbonic anhydrase inhibitors, or large doses of antacids should be avoided if possible. Otherwise, frequent urine pH testing may be considered. Some methenamine products may be used with antacids if dosing times are separated by at least one hour. Consult the manufacturer's product labeling for specific recommendations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 102265,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Palonosetron",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103766,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 104721,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105119,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pentamidine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107031,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108101,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108952,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 110356,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Vardenafil",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112596,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triethylenetetramine",
      "severity": "Moderate",
      "effect": "Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.",
      "management_text": "In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114098,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triptorelin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114302,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115368,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Paliperidone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118068,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118438,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Moderate",
      "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.",
      "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119213,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Moderate",
      "effect": "INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.",
      "management_text": "Separation of doses by two or more hours is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 121058,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Moxifloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 124713,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mycophenolate mofetil",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids may decrease the oral bioavailability of mycophenolic acid. The exact mechanism of interaction is unknown but may involve chelation with polyvalent ions in antacids or enhanced drug solubility induced by an increase in gastric pH, or both. The interaction has been reported with magnesium/aluminum-containing antacids.",
      "management_text": "Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.g., didanosine buffered tablets or pediatric oral solution) should separate the administration times of the medications by at least two hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 124927,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mycophenolic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids may decrease the oral bioavailability of mycophenolic acid. The exact mechanism of interaction is unknown but may involve chelation with polyvalent ions in antacids or enhanced drug solubility induced by an increase in gastric pH, or both. The interaction has been reported with magnesium/aluminum-containing antacids.",
      "management_text": "Patients treated with oral mycophenolic acid who require an antacid or antacid-containing preparation (e.g., didanosine buffered tablets or pediatric oral solution) should separate the administration times of the medications by at least two hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 125064,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mannitol",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 134682,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Methylprednisolone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 135789,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mefloquine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 136296,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Metamfetamine",
      "severity": "Moderate",
      "effect": "Gastrointestinal alkalinizing agents can increase the absorption of amphetamines by increasing the concentration of the non-ionized species of the amphetamine molecule.",
      "management_text": "Concomitant administration of amphetamines and gastrointestinal alkalinizing agents such as antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 137995,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Methazolamide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 138107,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Metolazone",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139174,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Midostaurin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 140482,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mifepristone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 140768,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mirtazapine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 141316,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nilotinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Antacids significantly decrease the oral bioavailability of nilotinib. The mechanism is decreased solubility of nilotinib due to antacid-induced gastric pH increases. Nilotinib's solubility is pH-dependent and it is insoluble at a pH of 4.5 or higher.",
      "management_text": "Patients treated with nilotinib should not take antacids or other agents with acid-neutralizing effects for at least 2 hours before or 2 hours after a nilotinib dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 144148,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nilutamide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 144403,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Norfloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 145523,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ofloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 146320,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ondansetron",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 147976,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Oxaliplatin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 148901,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Oxytocin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 149698,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Panobinostat",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 150505,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Paricalcitol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 150744,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pasireotide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151076,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pazopanib",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of pazopanib and reduce its concentrations in plasma. The solubility of pazopanib is pH-dependent, thus an increase in pH may interfere with its absorption.",
      "management_text": "Concomitant use of pazopanib with drugs that increase gastric pH should generally be avoided. If acid-suppression therapy is required, short-acting antacids should be considered, with dosing separated by several hours from pazopanib dosing.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151266,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Penicillamine",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral administration of aluminum, copper, iron, zinc, magnesium, and possibly other minerals such as calcium may decrease the gastrointestinal absorption of penicillamine, and vice versa. The proposed mechanism involves chelation of penicillamine to polyvalent cations, which leads to formation of a nonabsorbable complex.",
      "management_text": "Mineral supplements or other products containing polyvalent cations (e.g., antacids or preparations containing antacids such as didanosine buffered tablets or pediatric oral solution) should be administered at least two hours before or two hours after the penicillamine dose. In addition, pharmacologic response to penicillamine should be monitored more closely whenever these products are added to or withdrawn from therapy, and the penicillamine dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152178,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Perflutren",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152821,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids may decrease the bioavailability of phenytoin. The mechanism of interaction is unknown. However, some studies have failed to find a significant interaction with these antacids.",
      "management_text": "Given the narrow therapeutic index and the large interindividual variability in the pharmacokinetics of phenytoin, patients requiring concomitant antacid therapy should consider separating the times of administration by at least two to three hours if possible. Serum phenytoin levels and seizure activity should be monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 153855,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pimavanserin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 154121,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pimozide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 154365,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155922,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 156783,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Procainamide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 157205,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Propafenone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 157799,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pyrimethamine",
      "severity": "Moderate",
      "effect": "INTERVAL: The concomitant administration of antacids or absorbent antidiarrheals may significantly reduce the bioavailability of pyrimethamine by reducing its absorption. Therapeutic failure may result.",
      "management_text": "Antacids and antidiarrheals should be taken at least 2 to 3 hours apart from pyrimethamine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158493,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158806,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Quinine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 159176,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 159751,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Rifampicin",
      "severity": "Moderate",
      "effect": "INTERVAL: Limited data suggest that some antacids may decrease the oral bioavailability of rifampin. The mechanisms include decreased dissolution of rifampin in the presence of increased gastric pH and/or aluminum chelation with rifampin.",
      "management_text": "Rifampin should be administered at least 1 hour before antacids. Monitoring for altered therapeutic effect is advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 161485,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Romidepsin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162653,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Rosuvastatin",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of rosuvastatin. The mechanism of interaction has not been established but may involve a pH-dependent reduction in drug dissolution and absorption.",
      "management_text": "Until further data are available, patients treated with rosuvastatin should probably avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of rosuvastatin.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162973,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Salsalate",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 164131,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 165527,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sevoflurane",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 165706,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Solifenacin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166666,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sorafenib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166901,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 167100,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Moderate",
      "effect": "INTERVAL: Antacid-induced gastric pH changes may reduce binding of sucralfate with the gastrointestinal mucosa resulting in reduced therapeutic efficacy. In addition, aluminum may accumulate in patients with renal failure who are concomitantly taking sucralfate with aluminum-containing antacids.",
      "management_text": "Sucralfate and antacid doses should be separated by at least half an hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 167568,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sunitinib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 167897,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Moderate",
      "effect": "Coadministration with aluminum-magnesium hydroxide may increase tacrolimus blood concentrations in vivo. The mechanism of interaction is unknown.",
      "management_text": "Given the narrow therapeutic index and the large interindividual variability in the pharmacokinetics of tacrolimus, caution is advised if the drug is used in combination with aluminum and/or magnesium hydroxide. Pharmacologic response and tacrolimus blood levels should be monitored more closely whenever aluminum/magnesium hydroxide is added to or discontinued from therapy, and the immunosuppressant dosage adjusted as necessary. Patients should be advised to contact their doctor if they experience potential signs and symptoms of tacrolimus toxicity such as fever, infection, diarrhea, tremor, headache, fatigue, lethargy, and changes in motor function, mental status, or sensory function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 168263,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Telavancin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 169170,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 169391,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tetrabenazine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170534,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of tipranavir and reduce its concentrations in plasma. The mechanism of interaction has not been described. The clinical significance of these changes is unknown. However, subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.",
      "management_text": "Consideration should be given to separating tipranavir/ritonavir dosing from antacid administration to prevent reduced absorption of tipranavir.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 171910,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tolazamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 172585,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Toremifene",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 172961,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173103,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triamterene",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173856,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Vandetanib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175251,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175535,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175814,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176440,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 177257,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178156,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ergocalciferol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178811,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Eribulin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178964,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption.",
      "management_text": "If an antacid or other agent with acid-neutralizing effects is required during erlotinib therapy, it should be administered at least 4 hours before or 2 hours after the daily dose of erlotinib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179033,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179300,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 180474,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Etidronic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.",
      "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 180810,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181521,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Moderate",
      "effect": "INTERVAL: Medications that contain aluminum or magnesium hydroxide may decrease absorption of the cefaclor extended release formulation.",
      "management_text": "It is recommended that medications that contain aluminum or magnesium hydroxide not be administered within one hour of cefaclor extended release.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181571,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dihydrotachysterol",
      "severity": "Moderate",
      "effect": "Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to potentially additive pharmacologic effects. Chronic hypermagnesemia may have a role in the pathogenesis of adynamic bone disease in dialysis patients.",
      "management_text": "Patients on chronic renal dialysis treated with a vitamin D analog should avoid magnesium-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181575,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Moderate",
      "effect": "INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids with fexofenadine reduces its peak serum concentrations (Cmax) by 43% and area under the plasma concentration-time curve (AUC) by 41%. The clinical significance is unknown.",
      "management_text": "Fexofenadine should be administered at least 2 hours before antacids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181581,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181583,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181584,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Moderate",
      "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181596,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Trihexyphenidyl",
      "severity": "Moderate",
      "effect": "INTERVAL: Magnesium hydroxide may inhibit the absorption of trihexyphenidyl. The mechanism and clinical significance are unknown.",
      "management_text": "Doses should be separated by at least 2 hours to minimize the possibility of an interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181602,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Urea",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181604,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182646,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183040,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183585,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183801,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Foscarnet",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184291,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Gemifloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185283,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185838,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185966,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186254,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186316,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186575,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Histrelin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186717,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "INTERVAL: Concomitant administration of antacids or kaolin may reduce the oral bioavailability of chloroquine. The proposed mechanism is adsorption of chloroquine by polyvalent cations present in these agents. Delayed dissolution of chloroquine tablets in the presence of antacids may also be a contributing factor.",
      "management_text": "Chloroquine product labeling suggests separating the doses by at least 4 hours if concomitant therapy with antacids or kaolin is required. The same precaution may be applicable to hydroxychloroquine, although no data are available to support this recommendation. Some authorities recommend separating the dose of hydroxychloroquine from antacids and kaolin by at least 2 hours (AU).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187057,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187193,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ibutilide",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187439,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187832,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188345,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Riociguat",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of riociguat with antacids may reduce its gastrointestinal absorption. Riociguat exhibits pH-dependent solubility, with increased solubility at lower pH.",
      "management_text": "Antacids should not be taken within 1 hour of riociguat administration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188746,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of amprenavir and reduce its concentrations in plasma. Amprenavir solubility decreases with increasing pH, thus reduction in gastric acidity may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance. In contrast, the prodrug fosamprenavir appears to be less affected by antacids.",
      "management_text": "Amprenavir should be administered at least 1 hour before or after antacids or other oral preparations containing antacids (e.g., didanosine buffered tablets or pediatric oral solution).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188844,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bedaquiline",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189355,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190035,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Demeclocycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190486,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Iron",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190765,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Abarelix",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190836,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Astemizole",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190838,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bendroflumethiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190840,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Benzthiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190841,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cisapride",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190846,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Halofantrine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190852,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Hydroflumethiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190853,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Polythiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190859,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Probucol",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190860,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Terbutaline",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190865,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Terfenadine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190866,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Trichlormethiazide",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190869,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191275,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Acetohexamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192374,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bacampicillin",
      "severity": "Moderate",
      "effect": "Coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents with acid neutralizing or reducing effects may decrease the oral bioavailability and plasma concentrations of ampicillin from bacampicillin. The exact mechanism of interaction is unknown but may be related to degradation of the prodrug when gastric pH is increased.",
      "management_text": "The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. Preferably, these agents should be avoided during therapy with bacampicillin, or an alternative antibiotic be prescribed if these medications cannot be discontinued. Patients treated with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) may minimize the effects of the interaction with bacampicillin by separating the times of administration by at least 2 hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192375,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bepridil",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192376,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cinoxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192379,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Enoxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192381,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Grepafloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192382,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mesoridazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192387,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Methotrimeprazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192389,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nalidixic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192390,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Oxytetracycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.",
      "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192392,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Perphenazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192394,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Primaquine",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192395,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Promazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192396,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that can increase urinary pH such as antacids, carbonic anhydrase inhibitors, or urinary alkalinizers may decrease the urinary excretion of quinidine. The proposed mechanism is increased renal tubular reabsorption due to reduced ionization of quinidine in alkaline urine.",
      "management_text": "Caution is advised if quinidine is used with agents that can increase urinary pH. Quinidine levels may need to be monitored more closely following addition or discontinuation of these agents, and the quinidine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate quinidine toxicity such as tinnitus, hearing loss, visual disturbances, diarrhea, headache, dizziness, palpitations, syncope, or irregular heartbeats.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192398,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Salicylic acid (sodium)",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192400,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Sparfloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192401,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192403,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tiludronic acid",
      "severity": "Moderate",
      "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.",
      "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192404,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Tolbutamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192405,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192406,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triflupromazine",
      "severity": "Moderate",
      "effect": "Overuse of certain laxatives including magnesium hydroxide may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation. Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability. The interaction has been reported for chlorpromazine but may occur with other phenothiazines.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives including magnesium hydroxide. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192407,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Trovafloxacin",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192409,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 291363,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Acebutolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 4221,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Minor",
      "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 6657,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Minor",
      "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 6843,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Minor",
      "effect": "One study has suggested that coadministration of magnesium hydroxide and ibuprofen may significantly increase the area under the plasma concentration-time curve for ibuprofen. This increase may be clinically beneficial in circumstances in which a rapid response to ibuprofen is desirable.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 10325,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 19258,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Atenolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 35192,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Atorvastatin",
      "severity": "Minor",
      "effect": "The manufacturer reports that the coadministration of atorvastatin and Maalox TC (aluminum hydroxide-magnesium hydroxide) led to 35% decrease in plasma concentrations of atorvastatin. However, LDL-C reduction was not altered. The mechanism is unknown, but may be due to a chelation effect. The clinician may want to monitor the patient more closely for a decreased antihyperlipidemic effect.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 35849,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Axitinib",
      "severity": "Minor",
      "effect": "Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 36912,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 40563,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Betaxolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 42551,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 45042,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Minor",
      "effect": "Limited data indicate that aluminum and magnesium containing antacids may cause a small increase in the serum levels of capecitabine and one metabolite. The clinical significance of this interaction is not known.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 55349,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 55964,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 59820,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 62662,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Minor",
      "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 65651,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 69658,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 71152,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 71918,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 85358,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Minor",
      "effect": "Concurrent administration of antacids may decrease the oral bioavailability of digoxin and digitoxin. When digoxin and digitoxin are coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering digoxin or digitoxin at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 86735,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Minor",
      "effect": "Limited data suggest that concurrent administration of antacids may increase the bioavailability of valproic acid. The mechanism of interaction is unknown. Equivalent doses of antacids containing either aluminum hydroxide-magnesium trisilicate or calcium carbonate also increased the AUC of valproic acid, but the differences were not statistically significant.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 89227,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Minor",
      "effect": "Coadministration of enteric-coated duloxetine with substances that raise gastrointestinal pH may result in earlier release of duloxetine from the formulation. The enteric coating is intended to resist drug dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. However, coadministration with aluminum- and magnesium-containing antacids (51 mEq) or famotidine has been shown to have no significant effect on the rate or extent of duloxetine absorption following administration of a 40 mg oral dose.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 93730,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Minor",
      "effect": "Limited data suggest that concurrent administration of antacids may prolong the elimination half-life of erythromycin. The mechanism of interaction is unknown. These changes are unlikely to be of clinical importance, and no special precautions appear to be necessary.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 95633,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 98677,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Perindopril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 107471,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Minor",
      "effect": "Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 108613,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Minor",
      "effect": "Antacids and some oral aluminum, calcium, or magnesium containing preparations may decrease the gastrointestinal absorption of enteric-coated naproxen, which requires an acidic environment for dissolution. The proposed mechanism is an increase in gastric pH (i.e. decreased gastric acidity) produced by antacids. In patients treated with antacids, the possibility of a reduced or subtherapeutic response to enteric-coated naproxen should be considered. Concomitant use of these drugs is generally not recommended. Aluminum hydroxide and some magnesium-containing antacids have also been reported to reduce the absorption of regular naproxen. The interaction may be minimized by separating the times of administration by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 113312,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Trandolapril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 114015,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Vismodegib",
      "severity": "Minor",
      "effect": "The solubility of vismodegib is known to be pH-dependent (0.1 mcg/mL at pH 7 and 0.99 mg/mL at pH 1) and drugs that alter the pH of the upper gastrointestinal tract may affects its solubility and reduce its bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 115015,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Moexipril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 123973,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nadolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 125613,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Mefenamic acid",
      "severity": "Minor",
      "effect": "Orally administered magnesium-containing antacids may significantly increase the rate and extent of the absorption of mefenamic acid. No special precautions appear to be necessary.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 136104,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Metoprolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 139367,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Midazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 140136,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nebivolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 142610,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nitrofurantoin",
      "severity": "Minor",
      "effect": "The absorption of nitrofurantoin may be inhibited by magnesium-containing antacids. If a magnesium-containing product must be taken, administration of these agents should be separated by 2 to 3 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 145264,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Nizatidine",
      "severity": "Minor",
      "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 145326,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Pindolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 154600,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ponatinib",
      "severity": "Minor",
      "effect": "Coadministration with drugs that elevate the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids may decrease the oral bioavailability of ponatinib and reduce its concentrations in plasma. The aqueous solubility of ponatinib has been shown to be pH-dependent, with higher pH resulting in decreased solubility.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 155614,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158062,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Quazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 158575,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 159013,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 159520,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 169693,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Ticlopidine",
      "severity": "Minor",
      "effect": "Coadministration of oral medications that contain magnesium, aluminum, calcium, or sodium (i.e., antacids) has decreased ticlopidine serum concentrations by 18%. Administration of these drugs should be separated by at least three hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 171498,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Timolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 171706,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 173983,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 179784,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 184371,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Minor",
      "effect": "Aluminum hydroxide and magnesium hydroxide antacids may decrease the bioavailability of gabapentin by as much as 20%. A dose of aluminum or magnesium hydroxide should precede a dose of gabapentin by at least two hours. Other antacids that contain aluminum or magnesium may interact with gabapentin in a similar fashion.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 184839,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Minor",
      "effect": "One study has suggested that antacids such as aluminum hydroxide and magnesium hydroxide may decrease the bioavailability of indomethacin. However, the clinical significance of this interaction is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 188479,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Minor",
      "effect": "Limited data suggest that concurrent administration of magnesium hydroxide or magnesium oxide may increase the oral bioavailability of dicumarol. The mechanism of interaction is unknown. Given the widespread use of magnesium antacids and the limited evidence of a clinically significant interaction, no special precautions appear to be necessary when dicumarol is prescribed with magnesium hydroxide or magnesium oxide. However, a switch to a different antacid may be appropriate if an interaction is suspected.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 190847,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 190915,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Zalcitabine",
      "severity": "Minor",
      "effect": "Magnesium and aluminum antacids have been shown to reduce the area under the curve of zalcitabine. The mechanism has not been described but may be due to chelation or alteration in gastrointestinal pH. Zalcitabine should be administered 2 hours prior to a magnesium and/or aluminum-containing antacid. The clinical significance of this interaction is unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 191592,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Carteolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192378,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Digitoxin",
      "severity": "Minor",
      "effect": "Concurrent administration of antacids may decrease the oral bioavailability of digoxin and digitoxin. When digoxin and digitoxin are coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering digoxin or digitoxin at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192380,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192383,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Methdilazine",
      "severity": "Minor",
      "effect": "Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192388,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Oxazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192391,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Penbutolol",
      "severity": "Minor",
      "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192393,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Propiomazine",
      "severity": "Minor",
      "effect": "Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192397,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Thiethylperazine",
      "severity": "Minor",
      "effect": "Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192402,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Minor",
      "effect": "Coadministration with aluminum- or magnesium-containing antacids may decrease the serum concentrations of orally administered phenothiazines. The proposed mechanism is antacid adsorption resulting in reduced phenothiazine bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 192408,
      "ingredient1": "magnesium hydroxide"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Major",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may prolong or intensify the anticholinergic and CNS-depressant effects of doxylamine. In addition, concomitant use may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.",
      "management_text": "The use of doxylamine in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with doxylamine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 85899,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2319,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12541,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15230,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15601,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15706,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23949,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Hyoscyamine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25329,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Glycopyrronium",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50413,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Entacapone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57018,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73265,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85843,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85865,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Dronabinol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85867,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85868,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85869,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Echothiophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85870,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Eluxadoline",
      "severity": "Moderate",
      "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.",
      "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85871,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85872,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Esketamine",
      "severity": "Moderate",
      "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.",
      "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85873,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85874,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85875,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Eszopiclone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85876,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ethosuximide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85878,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ethotoin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85879,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85880,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Felbamate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85881,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fesoterodine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85882,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Flavoxate",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85883,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Moderate",
      "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.",
      "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85884,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85885,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85886,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85887,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85889,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85890,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85893,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Moderate",
      "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.",
      "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85894,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85895,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85896,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Isoflurophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85900,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fenfluramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 274164,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 274168,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Homatropine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300422,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14704,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22375,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ethchlorvynol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85877,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85892,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Ipratropium",
      "severity": "Moderate",
      "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.",
      "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85897,
      "ingredient1": "doxylamine succinate"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21489,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 119473,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 120971,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178445,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178463,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178470,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fosaprepitant",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178471,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178481,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Aminobenzoic acid",
      "severity": "Major",
      "effect": "The principal risk of eplerenone is hyperkalemia. Coadministration with potassium salts or potassium-sparing diuretics may increase this risk due to additive pharmacodynamic effects.",
      "management_text": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the use of eplerenone with potassium salts or potassium-sparing diuretics is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178501,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fosnetupitant",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 191029,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Major",
      "effect": "The principal risk of eplerenone is hyperkalemia. Coadministration with potassium salts or potassium-sparing diuretics may increase this risk due to additive pharmacodynamic effects.",
      "management_text": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the use of eplerenone with potassium salts or potassium-sparing diuretics is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 20986,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 95508,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178465,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Major",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "When used with moderate CYP450 3A4 inhibitors, the initial dosage of eplerenone should be reduced to 25 mg once daily for the treatment of hypertension. Patients already on eplerenone who start treatment with a moderate CYP450 3A4 inhibitor should have serum potassium and creatinine checked in 3 to 7 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178484,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 178486,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. In patients with renal impairment receiving these antihypertensive agents, concomitant use of NSAIDs has also resulted in severe hyperkalemia.",
      "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10244,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11182,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12551,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21995,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73272,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Moderate",
      "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.",
      "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97021,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Moderate",
      "effect": "Coadministration of eplerenone with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia due to additive pharmacodynamic effects.",
      "management_text": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, caution is advised if eplerenone is administered with ACE inhibitors or angiotensin II receptor antagonists. Periodic monitoring of serum potassium levels is recommended until the effect of eplerenone is established. In clinical trials, monitoring occurred every 2 weeks for the first 1 to 2 months, then monthly thereafter. Particular caution is warranted in patients with renal impairment, diabetes, old age, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119088,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119738,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.",
      "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178459,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. In patients with renal impairment receiving these antihypertensive agents, concomitant use of NSAIDs has also resulted in severe hyperkalemia.",
      "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178461,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Etravirine",
      "severity": "Moderate",
      "effect": "Coadministration with etravirine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by etravirine.",
      "management_text": "Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever etravirine is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178462,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. In patients with renal impairment receiving these antihypertensive agents, concomitant use of NSAIDs has also resulted in severe hyperkalemia.",
      "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178469,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.",
      "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178474,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Moderate",
      "effect": "Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.",
      "management_text": "Caution is advised during coadministration of these agents. Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178476,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178477,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178482,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178483,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Moderate",
      "effect": "Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.",
      "management_text": "Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 252178,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Moderate",
      "effect": "Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia.  Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists may increase the risk and/or severity of hyperkalemia.",
      "management_text": "Caution is advised when heparin or LMWHs are used with potassium-sparing diuretics or aldosterone receptor antagonists.  Serum potassium levels and renal function should be monitored regularly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 276041,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22393,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178444,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Ethchlorvynol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178460,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. In patients with renal impairment receiving these antihypertensive agents, concomitant use of NSAIDs has also resulted in severe hyperkalemia.",
      "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178464,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.",
      "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178466,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178467,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178468,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Moderate",
      "effect": "Coadministration of eplerenone with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia due to additive pharmacodynamic effects.",
      "management_text": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, caution is advised if eplerenone is administered with ACE inhibitors or angiotensin II receptor antagonists. Periodic monitoring of serum potassium levels is recommended until the effect of eplerenone is established. In clinical trials, monitoring occurred every 2 weeks for the first 1 to 2 months, then monthly thereafter. Particular caution is warranted in patients with renal impairment, diabetes, old age, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178472,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178478,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178480,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178485,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. In patients with renal impairment receiving these antihypertensive agents, concomitant use of NSAIDs has also resulted in severe hyperkalemia.",
      "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178487,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Minor",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of eplerenone, which is metabolized by the isoenzyme.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 178473,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Garlic",
      "severity": "Minor",
      "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 178475,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215309,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219285,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221224,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222882,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223550,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225443,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226438,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227114,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233498,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203511,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215080,
      "ingredient1": "Eplerenone"
    },
    {
      "ingredient2": "Dolutegravir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of UGT1A1 and CYP450 3A4 isoenzymes may significantly decrease the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4. Dolutegravir is also a substrate of UGT1A3, UGT1A9, and P-glycoprotein in vitro.",
      "management_text": "In patients with HIV-1 without integrase inhibitor (INI) resistance, some authorities recommend a dolutegravir dose of 50 mg twice daily for both adults and pediatric patients 12 years of age and older who weigh at least 40 kg when coadministered with potent UGT1A1 and CYP450 3A4 inducers including carbamazepine, phenytoin, phenobarbital, and St. John's Wort. However, other authorities advise that coadministration of dolutegravir with these inducers should be avoided. The safety and efficacy of dosages above 50 mg twice daily have not been evaluated. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible for INI-experienced patients with certain INI-associated resistance substitutions or clinically suspected INI resistance. In addition, concomitant use of potent UGT1A1 and CYP450 3A4 inducers with fixed-dose combination products containing dolutegravir is not recommended; however, when used in combination with carbamazepine, some authorities advise administration of an additional 50 mg daily dose of dolutegravir approximately 12 hours from the combination product. Local antiretroviral treatment experts should be consulted for current practice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 159,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Abemaciclib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which are substrates of the isoenzyme.",
      "management_text": "Concomitant use of abemaciclib with potent CYP450 3A4 inducers should generally be avoided. Alternative agents without CYP450 3A4 induction potential should be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 1226,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abiraterone, which is partially metabolized by the isoenzyme.",
      "management_text": "Concomitant use of abiraterone acetate with potent CYP450 3A4 inducers should generally be avoided. Otherwise, an increase in dosing frequency for abiraterone acetate to twice daily during the coadministration period (e.g., from 1000 mg once daily to 1000 mg twice daily) may be considered, although this dosage adjustment has not been studied clinically. The dosage should be adjusted back to the previous level when the CYP450 3A4 inducer is discontinued.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 1543,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Acalabrutinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of acalabrutinib with potent CYP450 3A4 inducers should generally be avoided. If coadministration cannot be avoided, the manufacturer recommends increasing the dosage of acalabrutinib to 200 mg twice daily.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2944,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 4882,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Alpelisib",
      "severity": "Major",
      "effect": "Coadministration of alpelisib with potent inducers of CYP450 3A4 may significantly reduce the plasma concentrations of alpelisib. The proposed mechanism, based on in vitro data, is increased clearance due to induction of CYP450 3A4, which is one of the routes of metabolism of alpelisib.",
      "management_text": "According to the manufacturer, concomitant use of alpelisib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18941,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cobicistat",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobicistat, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of antiretroviral regimens containing cobicistat with potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34870,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Axitinib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 36937,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bedaquiline",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline.",
      "management_text": "The concomitant use of bedaquiline with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39743,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of boceprevir, which is partially metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of boceprevir with potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39749,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of bosutinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of bosutinib with potent and moderate CYP450 3A4 inducers should be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39751,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme.",
      "management_text": "Concomitant use of brigatinib with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39752,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cabozantinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme.",
      "management_text": "Chronic use of potent CYP450 3A4 inducers during treatment with cabozantinib should be avoided whenever possible. If chronic coadministration is required, the daily dosage of cabozantinib should be increased in accordance with the prescribing information for the specific product. For the treatment of progressive, metastatic medullary thyroid cancer (capsule formulation), the recommendation is to increase cabozantinib dosage by 40 mg (e.g., from 140 mg to 180 mg daily or from 100 mg to 140 mg daily) as tolerated, not to exceed 180 mg/day.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39760,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Major",
      "effect": "Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed mechanism involves induction of CYP450 3A4, which is one of the primary enzymes responsible for the metabolic clearance of capmatinib.",
      "management_text": "Coadministration of capmatinib with strong or moderate CYP450 3A4 inducers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39761,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of ceritinib with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39764,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cobimetinib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of cobimetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39778,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Copanlisib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "Concomitant use of copanlisib with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39779,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Major",
      "effect": "Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of crizotinib with strong CYP450 3A4 inducers such as rifampin, carbamazepine, phenobarbital, and phenytoin should generally be avoided. Some authorities also advise against concomitant use with moderate CYP450 3A4 inducers.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39782,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Daclatasvir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of daclatasvir with potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39786,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Darolutamide",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Reduced efficacy of darolutamide may occur.",
      "management_text": "Concomitant use of darolutamide with dual P-gp and potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39788,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Major",
      "effect": "Coadministration with carbamazepine, phenobarbital, phenytoin, or primidone may significantly reduce the plasma concentrations of darunavir. The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of darunavir.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, darunavir should not be used in combination with carbamazepine, phenobarbital, phenytoin, or primidone.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39789,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of dasatinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of dasatinib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible during treatment with dasatinib. If coadministration is required, a dosage increase for dasatinib may be necessary depending on patient tolerability. Close monitoring for toxicities (e.g., myelosuppression, bleeding complications, fluid retention, QT prolongation) is recommended if the dosage of dasatinib is increased. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39790,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.",
      "management_text": "Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39791,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dezocine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39794,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doravirine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with potent CYP450 3A4 inducers is considered contraindicated. At least a 4-week cessation period is recommended prior to initiation of doravirine treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39802,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Drospirenone",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39807,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Duvelisib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of duvelisib with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39808,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Eliglustat",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.",
      "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39809,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Elvitegravir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39810,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may decrease the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. The extent to which CYP450 3A4 inducers may affect encorafenib exposure has not been studied.",
      "management_text": "Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39812,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39813,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Eravacycline",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of eravacycline, which undergoes oxidation by CYP450 3A4 and flavin monoxygenase (FMO).",
      "management_text": "Eravacycline dosage should be increased to 1.5 mg/kg every 12 hours when used with potent CYP450 3A4 inducers. No dosage adjustment is warranted when eravacycline is used with a weak or moderate inducer.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39814,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Erdafitinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.",
      "management_text": "Concomitant use of erdafitinib with potent inducers of CYP450 2C9 or 3A4 should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39815,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Etravirine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of etravirine, which is a substrate of CYP450 2C19, 2C9, and 3A4.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, etravirine should not be used with potent CYP450 inducers.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39828,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Everolimus",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the blood concentrations and pharmacologic effects of everolimus.",
      "management_text": "Concomitant use of everolimus with potent CYP450 3A4 and/or P-gp inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered. Some manufacturers recommend that, if concomitant use is unavoidable, the daily everolimus dose should be doubled to achieve the recommended therapeutic range for the condition being treated. Please refer to the manufacturer's labeling for specific dosing information. If the potent CYP450 3A4 and/or P-gp inducer is discontinued, the everolimus dosage should be returned to the dosage used before the potent inducer was commenced after a washout period of approximately 3 to 5 days. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase, and 2 weeks after discontinuation of the potent inducers.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39829,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.",
      "management_text": "According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39830,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19.",
      "management_text": "Concomitant use of flibanserin with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39832,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Major",
      "effect": "Coadministration of fostamatinib with potent inducers of CYP450 3A4 may significantly decrease exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration.",
      "management_text": "Concomitant use of fostamatinib with potent CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39838,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fostemsavir",
      "severity": "Major",
      "effect": "Coadministration of fostemsavir with potent CYP450 3A4 inducers may significantly decrease the plasma concentrations of temsavir, the active moiety of fostemsavir. According to the prescribing information, temsavir is a substrate of CYP450 3A4, esterases, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of fostemsavir with potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39839,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of glasdegib with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39841,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hemin",
      "severity": "Major",
      "effect": "Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin. In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.",
      "management_text": "Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39847,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ibrutinib",
      "severity": "Major",
      "effect": "Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of ibrutinib in combination with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, and rifamycins should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39852,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "Concomitant use of idelalisib with potent CYP450 3A4 or P-gp inducers such as carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John's wort should generally be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39853,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).",
      "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39858,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Istradefylline",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.",
      "management_text": "The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39863,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ivabradine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivabradine and its active N-desmethylated metabolite, both of which are primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of ivabradine with potent CYP450 3A4 inducers should generally be avoided. If coadministration is required, the possibility of diminished therapeutic response to ivabradine should be considered. Pharmacologic response to ivabradine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39865,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39866,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pitolisant",
      "severity": "Major",
      "effect": "Coadministration with potent CYP450 3A4 inducers may decrease the systemic exposure and efficacy of pitolisant. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of pitolisant, which has been shown to be metabolized by this isoenzyme.",
      "management_text": "Patients should be assessed for loss of efficacy of pitolisant following initiation of a potent CYP450 3A4 inducer, and the pitolisant dosage adjusted as necessary. For patients already receiving a stable dose of pitolisant 8.9 mg or 17.8 mg once daily, the dose of pitolisant should be increased to double the original daily dose (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days. The dosage of pitolisant should be reduced by half if concomitant use of a strong CYP450 3A4 inducer is discontinued.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39954,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A may significantly decrease the plasma concentrations of pralsetinib which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of pralsetinib with potent CYP450 3A inducers should generally be avoided. If coadministration with potent CYP450 3A inducers is necessary, the initial dose of pralsetinib should be doubled starting on Day 7 of coadministration with the strong CYP450 3A4 inducer. Once the potent CYP450 3A inducer has been discontinued for at least 14 days, the pralsetinib dose taken prior to initiating the potent CYP450 3A4 inducer may be resumed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39956,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pretomanid",
      "severity": "Major",
      "effect": "Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme.",
      "management_text": "The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39961,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme. The interaction has also been reported with phenytoin, another potent CYP450 3A4 inducer.",
      "management_text": "Increased dosages of quetiapine may be required during chronic treatment (greater than 7 to 14 days) with potent CYP450 3A4 inducers. The manufacturer recommends an increase of up to 5-fold the original dosage of quetiapine. Further adjustments should be made based on clinical response and tolerance. Continued treatment at higher dosages should only be considered following careful consideration of risks and benefits. When the CYP450 3A4 inducer is discontinued, the dosage of quetiapine should be reduced to the original level within 7 to 14 days.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39971,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ribociclib",
      "severity": "Major",
      "effect": "Coadministration with potent CYP450 3A4 inducers may significantly decrease the plasma concentrations and therapeutic effects of ribociclib, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of ribociclib with potent CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If coadministration is necessary, dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for therapeutic failure.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39978,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rilpivirine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of rilpivirine with potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39979,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rimegepant",
      "severity": "Major",
      "effect": "Coadministration with strong or moderate inducers of CYP450 3A4 may significantly reduce the plasma concentrations and therapeutic effects of rimegepant, which is primarily metabolized by the isoenzyme.",
      "management_text": "Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39980,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ripretinib",
      "severity": "Major",
      "effect": "Coadministration with strong inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.",
      "management_text": "Until more information is available, concomitant use of ripretinib with a strong CYP450 3A4 inducer is not recommended. Loss of anti-tumor activity may occur.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39981,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rivaroxaban",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of rivaroxaban with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39983,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rolapitant",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of rolapitant, which is primarily metabolized by the isoenzyme.",
      "management_text": "Rolapitant should not be used in patients who require chronic treatment with potent CYP450 3A4 inducers.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39984,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sacituzumab govitecan",
      "severity": "Major",
      "effect": "Coadministration with inducers of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) may significantly decrease the plasma concentrations of sacituzumab govitecan and its pharmacologically active metabolite, SN-38. The proposed mechanism involves decreased exposure to SN-38, a topoisomerase I inhibitor linked to sacituzumab govitecan, which is metabolized via UGT1A1. Loss of antineoplastic efficacy may occur.",
      "management_text": "Due to the potential loss of antitumour activity, concomitant use of sacituzumab govitecan with UGT1A1 inducers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39985,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39987,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Selumetinib",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.",
      "management_text": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39988,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Simeprevir",
      "severity": "Major",
      "effect": "Coadministration with potent and some moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of simeprevir, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of simeprevir in combination with potent and some moderate CYP450 3A4 inducers such as carbamazepine, dexamethasone, efavirenz, enzalutamide, eslicarbazepine, etravirine, nevirapine, oxcarbazepine, phenobarbital, phenytoin, primidone, rifamycins, St. John's wort, and tipranavir should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39990,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Major",
      "effect": "Coadministration with drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 may decrease the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/strong CYP450 3A4 dual inducer or a moderate CYP450 2C9 inducer in combination with a separate strong CYP450 3A4 inducer.",
      "management_text": "Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.g., carbamazepine, enzalutamide, rifampin) is not recommended for all patients. Concomitant use of siponimod and moderate or strong CYP450 3A4 inducers (e.g., apalutamide, bosentan, dabrafenib, dexamethasone, efavirenz, eslicarbazepine, etravirine, fosphenytoin, lorlatinib, lumacaftor, mitotane, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, St. John's wort) is not recommended for patients with CYP450 2C9*1/*3 and *2/*3 genotypes.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39991,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sodium oxybate",
      "severity": "Major",
      "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.",
      "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate. All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39994,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sofosbuvir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given with sofosbuvir in fixed-dose combination products such as ledipasvir and velpatasvir. Induction of P-gp-mediated efflux in the intestine decreases the oral bioavailability of these antiviral agents, which are substrates of the transporter. The interaction has been studied with rifampin, a potent inducer of P-gp and CYP450 isoenzymes.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of potent P-gp inducers should generally be avoided during treatment with sofosbuvir, given either as a single-ingredient product or as a fixed-dose combination product with ledipasvir or velpatasvir.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39995,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sonidegib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39996,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Stiripentol",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 1A2, 2C19, and/or 3A4 may significantly decrease the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways. Pharmacokinetic studies have not been conducted. Stiripentol itself is metabolized by these pathways and has been reported to also inhibit multiple CYP450 isoenzymes in vitro, thus both competitive and noncompetitive inhibition may occur. Coadministration of stiripentol with other anticonvulsants may increase central nervous system adverse effects such as somnolence, dizziness, confusion, difficulty concentrating, and impairment of psychomotor skills.",
      "management_text": "Concomitant use of stiripentol with potent CYP450 inducers such as carbamazepine, phenobarbital, phenytoin, and primidone should generally be avoided. If coadministration is required, patients should have plasma anticonvulsant concentrations monitored and dosage adjustments made accordingly. Patients should also be monitored for increased adverse effects such as dizziness, drowsiness, lethargy, confusion, diplopia, nystagmus, ataxia, dysarthria, hypothermia, and hypotension.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39999,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sunitinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.",
      "management_text": "Concomitant use of sunitinib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with minimal or no enzyme induction potential should be considered whenever possible. (Note: This recommendation is based on pharmacokinetic data from healthy volunteers as described above. The safety and efficacy of sunitinib with concomitant CYP450 3A4 inducers have not been established. )",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40001,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Suvorexant",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of suvorexant with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40002,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tapentadol",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40005,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tasimelteon",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 1A2 and 3A4 may significantly decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.",
      "management_text": "Concomitant use of tasimelteon with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40006,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tazemetostat",
      "severity": "Major",
      "effect": "Coadministration with moderate or potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40007,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Telaprevir",
      "severity": "Major",
      "effect": "Coadministration with certain anticonvulsants may significantly decrease the plasma concentrations of telaprevir. The mechanism involves induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of telaprevir and other protease inhibitors. Anticonvulsants that are considered potent inducers of CYP450 3A4 include carbamazepine, phenobarbital, and phenytoin.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic telaprevir levels, concomitant use with carbamazepine, phenobarbital, or phenytoin is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40008,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Temsirolimus",
      "severity": "Major",
      "effect": "Coadministration of temsirolimus with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.",
      "management_text": "Concomitant use of temsirolimus with potent CYP450 3A4 inducers should generally be avoided. If coadministration is required in patients treated with temsirolimus for renal cell carcinoma, the manufacturer recommends increasing the temsirolimus dosage from 25 mg to 50 mg once a week depending on patient tolerability. Based on pharmacokinetic studies, this dosage is predicted to adjust the sirolimus systemic exposure (AUC) to the range observed without inducers. However, clinical data are lacking. The dosage should be reduced to the normally recommended dosage (i.e., 25 mg once a week) following discontinuation of the potent CYP450 3A4 inducer.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40011,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ticagrelor",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of ticagrelor with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40018,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tofacitinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tofacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response.",
      "management_text": "The use of tofacitinib in combination with potent CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. The extent to which moderate CYP450 3A4 inducers interact with tofacitinib is unknown.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40019,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tolvaptan",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tolvaptan, which is primarily metabolized by the isoenzyme. When tolvaptan was administered with the potent CYP450 3A4 inducer rifampin, tolvaptan peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 85%.",
      "management_text": "Concomitant use of tolvaptan with potent CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, a dosage increase of tolvaptan may be required. Patient response should be closely monitored and the dosage adjusted accordingly.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40020,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trabectedin",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the potential for diminished pharmacologic effects of trabectedin in the presence of potent CYP450 3A4 inducers, concomitant use should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40023,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tucatinib",
      "severity": "Major",
      "effect": "Coadministration with potent CYP450 3A4 or moderate CYP450 2C8 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by CYP450 2C8 and to a lesser extent by CYP450 3A4.",
      "management_text": "Concomitant use of tucatinib with potent CYP450 3A4 or moderate CYP450 2C8 inducers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40036,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ubrogepant",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme. When ubrogepant was administered with the potent CYP450 3A4 inducer rifampin during in vivo studies, ubrogepant systemic exposure (AUC) decreased by 80%. Reduced efficacy of ubrogepant may occur.",
      "management_text": "Concomitant use of ubrogepant with potent CYP450 3A4 inducers should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40037,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Upadacitinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. The interaction may result in loss of or reduced clinical response.",
      "management_text": "The use of upadacitinib in combination with potent CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40038,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Valbenazine",
      "severity": "Major",
      "effect": "Coadministration of valbenazine with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of valbenazine and its active metabolite, which are substrates of the isoenzyme. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of valbenazine.",
      "management_text": "The use of valbenazine with strong CYP450 3A4 inducers should generally be avoided. If concomitant use is required, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may be required whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy. Alternative treatment may be considered if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40039,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of vemurafenib, which has been shown in vitro to be a substrate of the isoenzyme.",
      "management_text": "Concomitant use of vemurafenib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible during treatment with vemurafenib. If coadministration is required, the manufacturer recommends increasing the dose of vemurafenib by 240 mg (one tablet) as tolerated. Close monitoring for toxicities (e.g., QT prolongation, hepatotoxicity, nephrotoxicity, photosensitivity, dermatologic reactions, uveitis) is advised following dose increase. Two weeks after discontinuation of the strong CYP450 3A4 inducer, the vemurafenib dose that was taken prior to initiating the inducer may be resumed.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40041,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Venetoclax",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of venetoclax, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40042,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vorapaxar",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of vorapaxar, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of vorapaxar with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40046,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Voxelotor",
      "severity": "Major",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations and pharmacologic effects of voxelotor. The proposed mechanism is accelerated clearance of voxelotor due to induction of the CYP450 3A4 isoenzyme, which is the primary route of elimination of voxelotor.",
      "management_text": "The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible. If coadministration is required, the manufacturer recommends increasing the voxelotor dose to 2500 mg once daily. Pharmacologic response to voxelotor should also be monitored more closely.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40048,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Zanubrutinib",
      "severity": "Major",
      "effect": "Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40050,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Benzhydrocodone",
      "severity": "Major",
      "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids. Concomitant use may result in profound sedation, respiratory depression, coma, and death. On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate. Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.",
      "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate. Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation. A dosage adjustment for one or both drugs may be required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 41134,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Grazoprevir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme. Efavirenz is generally considered a moderate inducer of CYP450 3A4. More potent inducers such as carbamazepine or phenytoin may interact to an even greater extent.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 96693,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dienogest",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 179911,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Glecaprevir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of P-glycoprotein (P-gp) or CYP450 3A4 may significantly decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral agents are substrates of the P-gp efflux transporter, and glecaprevir is additionally a substrate of the CYP450 3A4 isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of glecaprevir and pibrentasvir with potent P-gp or CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185730,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fosnetupitant",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of netupitant.",
      "management_text": "Concomitant use of netupitant or its prodrug, fosnetupitant, should generally be avoided during chronic administration of potent CYP450 3A4 inducers due to the potential for reduced efficacy of netupitant.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 191124,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cabotegravir",
      "severity": "Major",
      "effect": "Coadministration with certain anticonvulsants or antimycobacterials may decrease the plasma concentrations of cabotegravir. The mechanism has not been clearly established but may involve induction of uridine diphosphate glucuronosyltransferase (UGT)-mediated metabolism of cabotegravir, which is primarily metabolized by UGT1A1 and to a lesser extent by UGT1A9.",
      "management_text": "Per the manufacturer, concomitant use of cabotegravir with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, or rifapentine is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 193141,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tivozanib",
      "severity": "Major",
      "effect": "Coadministration of tivozanib with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of tivozanib, which has been shown to be a substrate of the isoenzyme.",
      "management_text": "Due to the potential for reduced anti-tumor activity, concomitant use of tivozanib with a strong CYP450 3A4 inducer should generally be avoided. If coadministration is necessary, some authorities advise caution, with clinical and laboratory monitoring to be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 193160,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Procaine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247978,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ropivacaine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247982,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tetracaine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247993,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Prilocaine",
      "severity": "Major",
      "effect": "Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite.  Coadministration with other oxidizing agents that can also induce methemoglobinemia including other local anesthetics (e.g., benzocaine, lidocaine),antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Concomitant use of topical lidocaine-prilocaine formulations with other methemoglobin-inducing agents should be avoided in infants younger than 12 months of age.  Caution is advised when used in other patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 290447,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Desogestrel",
      "severity": "Major",
      "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 293067,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bictegravir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 295539,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dasabuvir",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir.",
      "management_text": "Concomitant use of ombitasvir/paritaprevir/ritonavir plus dasabuvir with potent CYP450 inducers such as carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's wort is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 298024,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Major",
      "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids. Concomitant use may result in profound sedation, respiratory depression, coma, and death. On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate. Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.",
      "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate. Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation. A dosage adjustment for one or both drugs may be required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2548,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Codeine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5315,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 6050,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10932,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Major",
      "effect": "Concurrent acute use of barbiturates and ethanol may result in additive CNS effects, including impaired coordination, sedation, and death. Tolerance of these agents may occur with chronic use. The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.",
      "management_text": "The combination of ethanol and barbiturates should be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 12740,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 14448,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "Coadministration with inducers of CYP450 3A4, such as rifamycins and St. John's wort, may decrease the serum concentrations of amiodarone and its metabolite desethylamiodarone (DEA) and result in therapeutic failure. The proposed mechanism is induction of CYP450 3A4 hepatic metabolism of amiodarone.",
      "management_text": "Monitoring serum amiodarone and DEA levels and patient's clinical status is recommended if CYP450 3A4 inducers are added to or deleted from a stable drug regimen that includes amiodarone. Alternative therapy or dosage adjustments may also be considered. Patients should be advised to notify their doctor if they experience worsening of their symptoms (e.g., palpitations or irregular heartbeat).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21725,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Major",
      "effect": "Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, pharmacologic response should be monitored more closely following the initiation or discontinuation of the CYP450 3A4 inducer, and the CCB dosage adjusted accordingly.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 23081,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Major",
      "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids. Concomitant use may result in profound sedation, respiratory depression, coma, and death. On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate. Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.",
      "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate. Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation. A dosage adjustment for one or both drugs may be required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 27297,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Major",
      "effect": "Barbiturates reduce the effects of oral anticoagulants by inducing their hepatic metabolism. Anticoagulant dosage requirements may be increased by 30% to 60%. After the barbiturate is discontinued, excessive anticoagulation and bleeding may occur if the anticoagulant dose is not reduced.",
      "management_text": "Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued. Alternatively, a benzodiazepine might be used instead of a barbiturate, if appropriate. Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39742,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.",
      "management_text": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39750,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Major",
      "effect": "Concomitant use of buprenorphine with other central nervous system (CNS) depressants has been associated with increased risk of buprenorphine overdose, severe respiratory depression, coma, and death. Coadministration with potent inducers of CYP450 3A4, including certain anticonvulsants such as carbamazepine, phenobarbital, phenytoin and primidone, may decrease the plasma concentrations of buprenorphine, which is primarily metabolized by the isoenzyme. Reduced efficacy or withdrawal symptoms may occur in patients maintained on buprenorphine.",
      "management_text": "Extreme caution is advised when prescribing buprenorphine in conjunction with other CNS depressants, or when prescribing buprenorphine to patients who are addicted to opioids and also abusing benzodiazepines or alcohol. Due to potential risk of overdose and death, dependence on sedative-hypnotics such as benzodiazepines or alcohol is considered a relative contraindication for office-based buprenorphine treatment of opioid addiction. Dosage reduction of CNS depressants, buprenorphine, or both should be considered if concomitant use is necessary. Pharmacologic response to buprenorphine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39756,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations and pharmacologic effects of buspirone, which is primarily metabolized by the isoenzyme. Conversely, discontinuation of an inducer may increase buspirone plasma concentrations and increase the risk of central nervous system depression and other adverse effects.",
      "management_text": "The potential for diminished pharmacologic effects of buspirone should be considered during coadministration with potent CYP450 3A4 inducers. Pharmacologic response to buspirone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buspirone dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39757,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Major",
      "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids. Concomitant use may result in profound sedation, respiratory depression, coma, and death. On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate. Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.",
      "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate. Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation. A dosage adjustment for one or both drugs may be required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39759,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of delavirdine, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of delavirdine with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39792,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Major",
      "effect": "Barbiturates reduce the effects of oral anticoagulants by inducing their hepatic metabolism. Anticoagulant dosage requirements may be increased by 30% to 60%. After the barbiturate is discontinued, excessive anticoagulation and bleeding may occur if the anticoagulant dose is not reduced.",
      "management_text": "Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued. Alternatively, a benzodiazepine might be used instead of a barbiturate, if appropriate. Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39797,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Etonogestrel",
      "severity": "Major",
      "effect": "RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones. There have been numerous case reports of menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) and unintended pregnancy occurring in women who received oral contraceptives with anticonvulsants. The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by some anticonvulsants.",
      "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39826,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Major",
      "effect": "Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.",
      "management_text": "Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers. For extended-release guanfacine, some manufacturers recommend increasing the dosage up to double the recommended level when initiating therapy in patients who are already receiving a CYP450 3A4 inducer. Further dosage adjustments may be required based on patient tolerance and response. If a CYP450 3A4 inducer is added to existing guanfacine therapy, the guanfacine dosage may be increased up to double the recommended level over 1 to 2 weeks. The dosage should be decreased to the recommended level over 1 to 2 weeks following discontinuation of the CYP450 3A4 inducer.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39844,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Major",
      "effect": "Rifampin and other strong CYP450 3A4 inducers may significantly decrease serum concentrations of haloperidol. The mechanism may be related to induction of the CYP450 3A4 metabolism of haloperidol.",
      "management_text": "Close observation for reduced clinical effects is recommended if these drugs must be used together. It may be necessary to adjust haloperidol dosage and/or dosage interval whenever a strong CYP450 3A4 inducer is added to or discontinued from therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39846,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39850,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme. Therapeutic failure may occur.",
      "management_text": "Concomitant use of imatinib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible. If coadministration with a potent CYP450 3A4 inducer is required, some authorities recommend increasing the dosage of imatinib by at least 50% while carefully monitoring clinical response. Imatinib dosages up to 1200 mg/day (600 mg twice daily) have been given to patients receiving concomitant potent CYP450 3A4 inducers.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39854,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4 to inactive substances, and induction of this process results in less of the drug available for conversion to SN-38 via hepatic carboxylesterases. Available data also suggest induction of other enzymatic pathways (e.g., UGT1A1; carboxylesterases) and drug transporters (e.g., multispecific organic anion transporter, or MRP2; mitoxantrone-resistance half transporter protein, or MXR) that may be involved in the clearance of irinotecan and/or SN-38, although the extent to which they contribute to the interaction is unknown.",
      "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inducers should generally be avoided. Consideration should be given to substituting nonenzyme-inducing agents at least one to two weeks prior to initiation of irinotecan therapy whenever possible.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39856,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Isradipine",
      "severity": "Major",
      "effect": "Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, pharmacologic response should be monitored more closely following the initiation or discontinuation of the CYP450 3A4 inducer, and the CCB dosage adjusted accordingly.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39862,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Praziquantel",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of praziquantel with potent CYP450 3A4 inducers is considered contraindicated because therapeutically effective blood levels of praziquantel may not be achieved.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39957,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Major",
      "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.",
      "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39967,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Major",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.",
      "management_text": "The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. The extent to which other, less potent CYP450 3A4 inducers may interact with ranolazine is unknown. Caution is advised if they are used with ranolazine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39976,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Remifentanil",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39977,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that are strong inducers of CYP450 3A4 may decrease the plasma concentrations of ritonavir and result in a potential loss of virologic response. The proposed mechanism is increased clearance due to induction of CYP450 3A4, which is the isoenzyme primarily responsible for the metabolism of ritonavir.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of ritonavir with drugs that are strong inducers of CYP450 3A4 is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39982,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations and pharmacologic effects of sirolimus. The mechanism probably involves reduced absorption as well as accelerated clearance of sirolimus due to induction of both intestinal P-glycoprotein drug efflux transporter and hepatic/intestinal CYP450 3A4 isoenzymes.",
      "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, the use of sirolimus with potent inducers of CYP450 3A4 and/or P-gp is not recommended. Alternative therapeutic agents with less enzyme induction potential should be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39992,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sufentanil",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40000,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations and pharmacologic effects of tacrolimus. The mechanism probably involves reduced absorption as well as accelerated clearance of tacrolimus due to induction of both intestinal P-glycoprotein drug efflux transporter and hepatic/intestinal CYP450 3A4 isoenzymes.",
      "management_text": "Given the risk of organ rejection associated with inadequate immunosuppressant levels, caution is advised if tacrolimus must be coadministered with potent inducers of CYP450 3A4 and/or P-gp. Tacrolimus blood levels should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of inducer therapy in patients who are stabilized on their anti-rejection regimen.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40003,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme. Enzyme activities usually return to normal 14 days after discontinuation of the inducing agent.",
      "management_text": "Telithromycin should not be used during or within 2 weeks after discontinuation of treatment with a potent CYP450 3A4 inducer.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40009,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Toremifene",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of toremifene.",
      "management_text": "Concomitant use of toremifene with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible during treatment with toremifene. If coadministration is required, a doubling of the toremifene dosage may be necessary depending on patient tolerability. Close monitoring for toxicities (e.g., QT prolongation, hepatotoxicity, hypercalcemia and tumor flare) is recommended if the dosage of toremifene is increased. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40022,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Major",
      "effect": "Coadministration with carbamazepine or long-acting barbiturates may significantly reduce the plasma concentrations of voriconazole. Although specific data are lacking, these agents are potent inducers of CYP450 isoenzymes that are responsible for the metabolic clearance of voriconazole and are expected to decrease the systemic exposure to voriconazole.",
      "management_text": "The use of voriconazole with carbamazepine or long-acting barbiturates is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40047,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Major",
      "effect": "Barbiturates reduce the effects of oral anticoagulants by inducing their hepatic metabolism. Anticoagulant dosage requirements may be increased by 30% to 60%. After the barbiturate is discontinued, excessive anticoagulation and bleeding may occur if the anticoagulant dose is not reduced.",
      "management_text": "Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued. Alternatively, a benzodiazepine might be used instead of a barbiturate, if appropriate. Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40049,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bupivacaine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247934,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chloroprocaine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247939,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Etidocaine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247950,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Afatinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter.",
      "management_text": "For patients who require chronic therapy with a P-gp inducer, it may be necessary to increase the daily dose of afatinib by 10 mg as tolerated. The previous dose may be resumed 2 to 3 days after discontinuation of the P-gp inducer.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10599,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24140,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Azilsartan medoxomil",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 37635,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39373,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Aminophylline",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.",
      "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39739,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amyl Nitrite",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39741,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bepridil",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39746,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bromocriptine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39753,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39762,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chloral hydrate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39765,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlormezanone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39768,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Moderate",
      "effect": "Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and antimicrobial effects of clindamycin, which is metabolized predominantly by the isoenzyme.",
      "management_text": "Monitor closely for diminished therapeutic response to clindamycin during coadministration with strong CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 inducer is added to or withdrawn from therapy with clindamycin. An alternative agent with no or minimal CYP450 3A4-inducing activity may also be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39774,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Corticotropin",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39780,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tetracosactide",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39781,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cyclizine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39783,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39787,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Digitoxin",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease serum digitoxin levels, possibly by increasing hepatic conversion of digitoxin to digoxin. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion.",
      "management_text": "Close observation for clinical and laboratory evidence of altered digitoxin effect is indicated if a barbiturate and digitoxin must be used together. Digoxin is not expected to be affected to the same extent.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39798,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ergometrine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.",
      "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39816,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39819,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Esterified estrogens",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39820,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Estrone sulfate",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39822,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39848,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "Coadministration with strong inducers of CYP450 2C8 or CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of hydroxychloroquine. When rifampin, a CYP450 2C8 and CYP450 3A4 strong inducer, was administered concomitantly with hydroxychloroquine, a lack of efficacy of hydroxychloroquine was reported. Because hydroxychloroquine and chloroquine and have similar structures and metabolic elimination pathways, a similar interaction could be observed for chloroquine.Chloroquine or hydroxychloroquine may lower the convulsive threshold, which may antagonize the action of antiepileptic medications. Seizures have been rarely reported in patients on chloroquine or hydroxychloroquine therapy. The mechanism is unknown.",
      "management_text": "Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a strong CYP450 3A4 or 2C8 inducer. Clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 or 2C8 inducer is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. The potential risks and benefits should be evaluated prior to initiating chloroquine or hydroxychloroquine in patients on anticonvulsant therapy. In addition, patients with a history of epilepsy should be advised about the risk of chloroquine/hydroxychloroquine-induced seizures. Alternative anti-malarial agents may be required. Local treatment guidelines should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39851,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.",
      "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39859,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Polythiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39955,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Quazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39970,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Quinestrol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39972,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Thiothixene",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40016,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Thyroid, porcine",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease exogenous thyroid plasma concentrations resulting in elevated thyroid stimulating hormone (TSH) and exacerbation of hypothyroidism. The mechanism may be induction of hepatic CYP450 enzymes responsible for thyroxine (T4) and triiodothyronine (T3) metabolism. Clinical data are limited.",
      "management_text": "Clinical monitoring of patient response, including laboratory serum TSH concentrations, is recommended. Adjustment of thyroid replacement dosage may be indicated when initiating or discontinuing barbiturate therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40017,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40030,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bendamustine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of bendamustine and increase the plasma concentrations of its pharmacologically active metabolites. In vitro, bendamustine has been shown to undergo metabolism via CYP450 1A2 to two minor cytotoxic metabolites, M3 and M4.",
      "management_text": "Caution is advised if bendamustine is used in combination with CYP450 1A2 inducers. Patients should be monitored for potentially altered effects of bendamustine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40733,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Betrixaban",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of P-glycoprotein (P-gp) may reduce the systemic exposure and pharmacodynamic effects of betrixaban, which is a substrate of the efflux transporter.",
      "management_text": "The use of betrixaban with P-gp inducers should generally be avoided. If use is unavoidable, pharmacologic response to betrixaban should be monitored closely.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 42901,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Binimetinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 1A2, P-glycoprotein (P-gp), and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7 may decrease the plasma levels and therapeutic efficacy of binimetinib. The proposed mechanism involves enhanced metabolic clearance of binimetinib through induction of CYP450 1A2, P-gp, and/or UGT 1A1 or 2B7.",
      "management_text": "Until further information is available, caution is recommended if binimetinib must be used concomitantly with CYP450 1A2, P-gp, and/or UGT 1A1 or 2B7 inducers. Pharmacologic response to binimetinib should be monitored more closely whenever a CYP450 1A2, P-gp, and/or UGT 1A1 or 2B7 inducer is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43967,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Brexanolone",
      "severity": "Moderate",
      "effect": "Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.",
      "management_text": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47465,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Brexpiprazole",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of brexpiprazole, which is partially metabolized by this isoenzyme. According to product labeling, administration of brexpiprazole with a potent 3A4 inducer (rifampin) resulted in an approximately 75% decrease in AUC.",
      "management_text": "During concomitant use with a potent 3A4 inducer, the usual dose of brexpiprazole should be doubled over one to two weeks. When the inducer is discontinued, the brexpiprazole dose should be decreased to its original level over one to two weeks. It is advisable to monitor patients for clinical response.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47839,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Brivaracetam",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 isoenzymes may decrease the plasma concentrations of brivaracetam, which is partially metabolized by CYP450 2C19.",
      "management_text": "The potential for diminished pharmacologic effects of brivaracetam should be considered during coadministration with potent CYP450 enzyme inducers. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 inducer is added to or withdrawn from therapy. For patients receiving concomitant carbamazepine or phenytoin therapy, blood levels should be monitored following initiation or discontinuation of brivaracetam. Dosage reductions for carbamazepine and phenytoin may be required if tolerability issues arise.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 49323,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cabazitaxel",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. However, no formal drug interaction studies have been conducted.",
      "management_text": "Concomitant use of cabazitaxel with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided. The extent to which other, less potent CYP450 3A4 inducers may interact with cabazitaxel is unknown. Caution is advised if they are used with cabazitaxel.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52786,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "Coadministration with uridine diphosphoglucuronate-glucuronosyltransferase (UGT) inducers such as rifampin, phenytoin, phenobarbital, and ritonavir may decrease area under the curve (AUC) of canagliflozin by up to 51%.",
      "management_text": "If coadministration with a UGT inducer is required, a higher dose of canagliflozin may be needed based on tolerability, glycemic control, and renal function. Monitor glycemic control and refer to the product labeling for specific guidelines on dosing adjustments.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54397,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Canakinumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54645,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cannabidiol",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or CYP450 2C19 may decrease the plasma concentrations of cannabidiol. The proposed mechanism of action is induction of CYP450 3A4 and/or 2C19-mediated metabolism of cannabidiol.",
      "management_text": "A dosage increase of cannabidiol up to 2-fold may be required when coadministered with potent inducers of CYP450 3A4 and/or CYP450 2C19 based on clinical response and tolerability.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55122,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cariprazine",
      "severity": "Moderate",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites. Cariprazine is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2D6 to desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR). DCAR is further metabolized to DDCAR by CYP450 3A4 and 2D6, and DDCAR is then metabolized by CYP450 3A4 to a hydroxylated metabolite. Both DCAR and DDCAR have in vitro receptor binding profiles similar to the parent drug and are considered pharmacologically equipotent to cariprazine.",
      "management_text": "Concomitant use of cariprazine with potent or moderate CYP450 3A4 inducers has not been evaluated and is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58667,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cenobamate",
      "severity": "Moderate",
      "effect": "Coadministration with cenobamate may increase the plasma concentrations and pharmacologic effects of phenobarbital. The proposed mechanism is cenobamate-mediated inhibition of CYP450 2C19, an isoenzyme involved in the hepatic metabolism of phenobarbital.",
      "management_text": "Caution is recommended during concomitant use of cenobamate and phenobarbital. Clinical and/or laboratory monitoring are advisable whenever cenobamate is added to or withdrawn from therapy, and the phenobarbital dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60864,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Certolizumab pegol",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 61718,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cholic Acid",
      "severity": "Moderate",
      "effect": "Coadministration of phenobarbital with cholic acid may decrease the therapeutic effects of cholic acid. The mechanism of this interaction has not been delineated.",
      "management_text": "The use of phenobarbital with cholic acid in patients with 3-beta-hydroxy delta-5 C27-steroid oxidoreductase deficiency or delta-4 3-oxosteroid 5-beta-reductase deficiency should generally be avoided. However, some authorities consider use of phenobarbital with cholic acid in this patient population as contraindicated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64837,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clevidipine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69388,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70814,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of dabrafenib, which is primarily metabolized by these isoenzymes.",
      "management_text": "Concomitant use of dabrafenib with potent CYP450 2C8 or 3A4 inducers should generally be avoided. Otherwise, patients should be closely monitored for potential loss of efficacy of dabrafenib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77771,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Saxagliptin",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of saxagliptin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Dosage adjustment of saxagliptin is not necessary during coadministration with rifampin or other CYP450 3A4 inducers. However, glycemic control should be closely monitored, and the physician notified if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 79115,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of uridine diphosphate glucuronosyltransferase (UGT) may decrease the plasma concentrations of deferasirox, which is primarily metabolized by UGT1A1- and UGT1A3-mediated glucuronidation.",
      "management_text": "The concomitant use of deferasirox with potent UGT inducers such as rifampin, phenytoin, phenobarbital, carbamazepine, and ritonavir should generally be avoided. Otherwise, consideration may be given to increasing the initial dosage of deferasirox by 50% during coadministration with potent UGT inducers, with subsequent adjustments made according to serum ferritin levels and clinical response.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81644,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84160,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Deutetrabenazine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84479,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Difenoxin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 86549,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of docetaxel, which is a substrate of the isoenzyme. Rifampin and hyperforin, a component of St. John's wort, have been shown to significantly induce the in vitro metabolism of docetaxel in human hepatocyte cultures.",
      "management_text": "Coadministration of docetaxel with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of docetaxel underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with docetaxel is unknown.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 89532,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doxercalciferol",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin D analogs. These agents are thought to induce the hepatic conversion of vitamin D to inactive metabolites and have been shown to reduce circulating levels of active vitamin D, sometimes accompanied by reduced serum calcium and increased parathyroid hormone levels. Patients on long-term anticonvulsant therapy have occasionally developed osteomalacia, presumably due to interference with vitamin D and calcium metabolism. There have also been isolated reports of patients who responded poorly to vitamin D supplements during treatment with phenytoin and/or primidone.",
      "management_text": "Patients receiving vitamin D analogs with CYP450 inducers should be monitored for potentially reduced vitamin D effects. Dosage adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91841,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of dronedarone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of dronedarone with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided. The extent to which other, less potent CYP450 3A4 inducers may interact with dronedarone is unknown. Caution is advised if they are used with dronedarone.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92682,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Edoxaban",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of P-glycoprotein (P-gp) may reduce the bioavailability of edoxaban, which is a substrate of the efflux transporter.",
      "management_text": "Caution is advised if edoxaban is used with P-gp inducers. Pharmacologic response to edoxaban should be monitored more closely whenever a P-gp inducer is added to or withdrawn from therapy, and the edoxaban dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 95392,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Elagolix",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the metabolic isoenzyme and efflux transporter.",
      "management_text": "The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments or a dose adjustment of elagolix may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96502,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Emapalumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97930,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "Coadministration of empagliflozin with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations and efficacy of empagliflozin, which is primarily metabolized in vitro by UGT1A3, 1A8, 1A9, and 2B7.",
      "management_text": "Coadministration of empagliflozin with UGT inducers should be avoided if possible. If concomitant use is required, dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from empagliflozin therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98122,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118510,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pimavanserin",
      "severity": "Moderate",
      "effect": "Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 154129,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pomalidomide",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 1A2, CYP450 3A4, and/or P-glycoprotein may decrease the plasma concentrations of pomalidomide, which has been shown to be primarily metabolized by these isoenzymes and also a substrate of the efflux transporter.",
      "management_text": "Concomitant use of pomalidomide with potent inducers of CYP450 isoenzymes and/or P-glycoprotein should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155440,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ponatinib",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.",
      "management_text": "Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided unless the benefit outweighs the potential risk of ponatinib underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ponatinib is unknown.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155620,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Moderate",
      "effect": "Phenytoin and other enzyme-inducing anticonvulsants may decrease the plasma concentration of posaconazole. The mechanism is induction of posaconazole clearance via the UDP-glucuronosyltransferase glucuronidation and P-glycoprotein efflux pathways.",
      "management_text": "Use of posaconazole in combination with enzyme-inducing anticonvulsants should generally be avoided unless the potential benefit outweighs the risk. If coadministration is necessary, patient response to the antifungal agent must be closely monitored. If phenytoin is used, pharmacologic response and serum phenytoin levels should also be monitored closely following initiation or discontinuation of posaconazole, and the phenytoin dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155930,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rasagiline",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 160200,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Regorafenib",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of regorafenib.",
      "management_text": "The use of regorafenib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and St. John's wort should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 160338,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Remdesivir",
      "severity": "Moderate",
      "effect": "Theoretical concerns exist that coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of remdesivir, which has been shown in vitro to be a substrate of the metabolic isoenzyme and efflux transporter.",
      "management_text": "Until more information is available, some experts recommend avoiding the concomitant use of remdesivir with potent CYP450 3A4 or P-gp inducers.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 160463,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Remimazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 160736,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rilonacept",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 161831,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Roflumilast",
      "severity": "Moderate",
      "effect": "Coadministration with potent CYP450 inducers may significantly reduce the systemic exposure to roflumilast and its pharmacologically active N-oxide metabolite, the former of which is metabolized by CYP450 1A2 and 3A4, and the latter of which is metabolized by CYP450 2C19 and 3A4.",
      "management_text": "Due to the potential for reduced therapeutic effectiveness of roflumilast, concomitant use with potent CYP450 enzyme inducers such as carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's wort is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162444,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Romidepsin",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may increase the plasma concentrations of romidepsin. The exact mechanism of interaction has not been established, particularly since romidepsin is a substrate of CYP450 3A4, and induction of the isoenzyme would be expected to reduce its plasma concentration.",
      "management_text": "The use of romidepsin in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided if possible. Alternative treatment lacking CYP450 3A4-inducing activity should be considered in patients receiving romidepsin. If concomitant use is required, patients should be closely monitored for development of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162660,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rotigotine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 163054,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rucaparib",
      "severity": "Moderate",
      "effect": "Coadministration with strong CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of rucaparib, which has been shown in vitro to be a substrate of the isoenzyme.",
      "management_text": "Caution is advised if rucaparib is used concomitantly with potent CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy with rucaparib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 163219,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ruxolitinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer. However, patients should be closely monitored and the dose titrated based on safety and efficacy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 163600,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sarilumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 164397,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Satralizumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 164467,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Secukinumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 164862,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Silodosin",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of silodosin, which is a substrate of both the isoenzyme and efflux transporter.",
      "management_text": "The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 165937,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Siltuximab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166018,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Solifenacin",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of solifenacin, which has been shown to be a substrate of the isoenzyme in vitro.",
      "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166678,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Teriflunomide",
      "severity": "Moderate",
      "effect": "Coadministration of teriflunomide with known strong inducers of CYP450 isoenzymes and efflux transporters, such as phenobarbital and St. John's wort, may decrease the plasma concentrations and therapeutic effects of teriflunomide. The proposed mechanism is induction of CYP450 isoenzymes and/or efflux transporters responsible for the metabolic clearance of teriflunomide.",
      "management_text": "Caution and close clinical and laboratory monitoring are recommended if teriflunomide is coadministered with strong inducers of CYP450 isoenzymes and/or efflux transporters. Dosage adjustments may be required whenever a strong inducer is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170355,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tetrabenazine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170551,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tocilizumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 172311,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ulipristal",
      "severity": "Moderate",
      "effect": "The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme. Induction of CYP450 3A4 may last for up to 4 weeks after discontinuation of the enzyme inducer.",
      "management_text": "Concomitant use of ulipristal with CYP450 3A4 inducers should be avoided if possible and nonhormonal emergency contraception should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174704,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ustekinumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174917,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vandetanib",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of vandetanib, which is a substrate of the isoenzyme.",
      "management_text": "Concomitant use of vandetanib with potent CYP450 3A4 inducers should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175257,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vilazodone",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of vilazodone, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic response to vilazodone should be considered during coadministration with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, and rifampin. When concomitant use is prescribed for greater than 14 days, an increase in the vilazodone dosage up to 2-fold may be considered depending on clinical response, up to a maximum of 80 mg daily. Following discontinuation of the CYP450 3A4 inducer, the dosage of vilazodone should be returned to the original level in 14 days.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176098,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vortioxetine",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of vortioxetine, which is primarily metabolized by CYP450 2D6.",
      "management_text": "An increase in the dosage of vortioxetine should be considered when used in combination with potent CYP450 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifamycins) for greater than 14 days, up to a maximum of three times the original dosage depending on clinical response. Following discontinuation of the potent CYP450 inducer, vortioxetine dosage should be returned to the original level within 14 days. Other known CYP450 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, enzalutamide, efavirenz, etravirine, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with vortioxetine is unknown.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176574,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ziconotide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 177070,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.",
      "management_text": "Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort should generally be avoided. Moderate inducers such as bosentan, efavirenz, etravirine, modafinil, nafcillin, and nevirapine should also be avoided if possible. The extent to which other, less potent CYP450 3A4 inducers may interact with enzalutamide is unknown. Caution is advised if they are used with enzalutamide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178166,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179319,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Esketamine",
      "severity": "Moderate",
      "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.",
      "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179423,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Coadministration of eslicarbazepine acetate with phenobarbital may decrease the systemic exposure to the active metabolite, eslicarbazepine. The proposed mechanism is phenobarbital induction of the glucuronidation of eslicarbazepine.",
      "management_text": "The potential for diminished therapeutic effects of eslicarbazepine should be considered when prescribed in combination with phenobarbital or primidone, a drug that is partially metabolized to phenobarbital. A dosage increase for eslicarbazepine acetate may be required based on efficacy and tolerability.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179533,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181536,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fesoterodine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.",
      "management_text": "No dosing adjustments are recommended when fesoterodine is used with CYP450 3A4 inducers. However, the possibility of diminished therapeutic effects should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182279,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184149,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fosaprepitant",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John's wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184218,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "Barbiturates may induce or inhibit the metabolism of phenytoin. Plasma phenytoin concentrations may be decreased or increased. The mechanism are induction of hepatic CYP450 phenytoin metabolism by therapeutic doses of barbiturates, and competitive inhibition of metabolism by large doses.",
      "management_text": "Close laboratory and clinical observation for altered effects of both agents is recommended when doses of either agent are started, changed, or discontinued. Patients should be advised to notify their physician if they experience loss of seizure control or excessive or prolonged sedative effects. It may be necessary to alter the dosage of one or both of the drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184503,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.",
      "management_text": "The potential for diminished pharmacologic effects of gilteritinib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185508,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186139,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Guselkumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186470,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187850,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Activated charcoal",
      "severity": "Moderate",
      "effect": "Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects or of the toxicity of many drugs. Activated charcoal may adsorb any therapeutic agents administered while it is in the gastrointestinal tract.",
      "management_text": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications. If concomitant use is necessary, the dosage or route of administration may need to be altered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188706,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Riociguat",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of riociguat, which is partially metabolized by the isoenzyme.",
      "management_text": "The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of riociguat adjusted as necessary. Data are not available to guide dosing of riociguat when coadministered with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort. Alternative agents with no or minimal CYP450 3A4-inducing activity should be considered whenever possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188752,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ginkgo biloba",
      "severity": "Moderate",
      "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures and may antagonize the effects of anticonvulsants. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with anticonvulsants should preferably avoid the use of products containing ginkgo biloba.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191404,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clofedanol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193143,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorcyclizine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193144,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fospropofol",
      "severity": "Moderate",
      "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.",
      "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193147,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Glycerol phenylbutyrate",
      "severity": "Moderate",
      "effect": "Drugs that can increase plasma ammonia levels such as corticosteroids, haloperidol, or the anticonvulsants carbamazepine, topiramate, and phenobarbital may interfere with the therapeutic effects of phenylbutyrate therapy in the management of urea cycle disorders. Corticosteroids can cause the breakdown of body protein, which may lead to increased ammonia levels. The use of haloperidol has been associated with hyperammonemia in a young child with citrullinemia, an inherited disorder of ammonia excretion.",
      "management_text": "Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193148,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193149,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "St. John's Wort",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193157,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Valerian",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193163,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Safinamide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 245672,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Scopolamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247333,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Selinexor",
      "severity": "Moderate",
      "effect": "Coadministration with potent CYP450 3A4 inducers may decrease the plasma concentrations and pharmacologic effects of selinexor, which is metabolized by the isoenzyme along with multiple UDP-glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs).",
      "management_text": "Caution and clinical monitoring for reduced therapeutic efficacy are recommended with the concomitant use of selinexor with potent CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247581,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rifapentine",
      "severity": "Moderate",
      "effect": "Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes.  The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine.",
      "management_text": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247980,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Selegiline",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247983,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Silver nitrate (topical)",
      "severity": "Moderate",
      "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247984,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Silver sulfadiazine (topical)",
      "severity": "Moderate",
      "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247985,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Phenyltoloxamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 289466,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Reserpine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 292654,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diphenoxylate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 293833,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bazedoxifene",
      "severity": "Moderate",
      "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.",
      "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 295258,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dichloralphenazone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300969,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorpheniramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 3824,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease serum concentrations and half-life of oral doxycycline to subtherapeutic levels. The mechanism may be induction of the hepatic metabolism of doxycycline.",
      "management_text": "Other tetracyclines which are primarily renally excreted (e.g., tetracycline, demeclocycline, oxytetracycline) should be considered, as they are not expected to interact. If the patient must receive doxycycline, close monitoring for altered efficacy is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7940,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Adalimumab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 9326,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11364,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Albendazole",
      "severity": "Moderate",
      "effect": "Coadministration with anticonvulsant drugs such as carbamazepine, phenytoin, phenobarbital, and primidone may decrease the plasma concentrations and half-life of the active metabolite of albendazole, albendazole sulfoxide. The mechanism is unknown, but induction of hepatic metabolism by these anticonvulsant drugs has been proposed.",
      "management_text": "Caution and monitoring for altered clinical efficacy are recommended if albendazole is used concomitantly with anticonvulsant drugs such as carbamazepine, phenytoin, phenobarbital, or primidone in patients treated for systemic helminthic infections. Dose adjustments or alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11743,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Aldesleukin",
      "severity": "Moderate",
      "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS-depressant effects with aldesleukin. Aldesleukin has been associated with CNS effects including depression, confusion, and drowsiness, which may progress to coma.",
      "management_text": "Caution is advised if aldesleukin is used with sedatives, hypnotics, tranquilizers, or other CNS-active medications. Patients should be monitored for CNS depression and other CNS adverse effects. Treatment with aldesleukin should be discontinued if severe lethargy or somnolence develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13186,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Alefacept",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13586,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cholecalciferol",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin D analogs. These agents are thought to induce the hepatic conversion of vitamin D to inactive metabolites and have been shown to reduce circulating levels of active vitamin D, sometimes accompanied by reduced serum calcium and increased parathyroid hormone levels. Patients on long-term anticonvulsant therapy have occasionally developed osteomalacia, presumably due to interference with vitamin D and calcium metabolism. There have also been isolated reports of patients who responded poorly to vitamin D supplements during treatment with phenytoin and/or primidone.",
      "management_text": "Patients receiving vitamin D analogs with CYP450 inducers should be monitored for potentially reduced vitamin D effects. Dosage adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14072,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16348,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17230,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Moderate",
      "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.",
      "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17517,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 2C8 may decrease the plasma concentrations of pioglitazone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Because the antidiabetic effect of pioglitazone is dose- and concentration-dependent, patients treated concomitantly with a CYP450 2C8 inducer may require a higher dosage of pioglitazone. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of the CYP450 2C8 inducer, and the pioglitazone dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18379,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18646,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19329,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Altretamine",
      "severity": "Moderate",
      "effect": "According to a rat model, the coadministration with phenobarbital (PB) may decrease the plasma, liver, and tumor concentrations of altretamine, as well as reduce its antitumor activity. The likely mechanism is PB induction of altretamine metabolism via CYP450 isoenzymes, resulting in decreased time of exposure of tumor cells to altretamine and its active metabolites.",
      "management_text": "Until further data are available, the concomitant use of altretamine and phenobarbital should probably be avoided if possible. The same precaution may be applicable to other barbiturates because of their potential to induce CYP450 isoenzymes.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19814,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21091,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22625,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 1A2 may decrease the plasma concentrations of anagrelide and increase the plasma concentrations of its pharmacologically active metabolite, 3-hydroxy-anagrelide.",
      "management_text": "Clinical and laboratory monitoring are recommended if anagrelide is used in combination with a CYP450 1A2 inducer. Dose adjustments may also be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24887,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Anakinra",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25190,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Propofol",
      "severity": "Moderate",
      "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.",
      "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25811,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Moderate",
      "effect": "Coadministration with fenofibrate may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of CYP450 2C19, 2A6, and 2C9 isoenzymes. The proposed mechanism, based on in vitro data, is decreased clearance due to fenofibrate-mediated inhibition of CYP450 2C19, 2A6, and 2C9.",
      "management_text": "Until more information is available, caution is advised if fenofibrate is used concomitantly with drugs that are substrates of CYP450 2C19, 2A6, or 2C9 isoenzymes, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever fenofibrate is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26687,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Moderate",
      "effect": "Excessive use or abrupt discontinuation of barbiturates and other sedatives after chronic ingestion may precipitate seizures in patients receiving bupropion. Theoretically, barbiturates may also decrease the plasma concentrations and pharmacologic effects of bupropion due to induction of hepatic CYP450 isoenzymes.",
      "management_text": "Pharmacologic response to bupropion should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the bupropion dosage adjusted as necessary. Although barbiturates and other sedatives may be prescribed to treat agitation, anxiety, and insomnia associated with bupropion use, patients should be alerted to the possibility of an increased risk of seizures during excessive exposure to these drugs. Patients should not attempt to alter the dosages or discontinue the medications on their own without consulting with their physician. The use of bupropion is contraindicated in patients undergoing abrupt discontinuation of sedatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28449,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31068,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Azelastine (nasal)",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34333,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Benzocaine (topical)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38100,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Baclofen",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38403,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Conjugated estrogens",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39685,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39740,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bendroflumethiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39744,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Benzthiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39745,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39747,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Biperiden",
      "severity": "Moderate",
      "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol. These agents individually can cause cognitive and psychomotor impairment, drowsiness, and dizziness, thus concomitant use may result in more potent effects. In addition, the potential for abuse may be increased when central anticholinergic agents are combined with these drugs.",
      "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39748,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Brompheniramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39754,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39755,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Butabarbital",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39758,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39763,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "Barbiturates may increase the hepatic metabolism of chloramphenicol. Serum chloramphenicol levels and effectiveness may be decreased. Coadministration also may enhance the pharmacologic effect of barbiturates. The proposed mechanism is induction of chloramphenicol metabolism by barbiturates and inhibition of barbiturate metabolism by chloramphenicol.",
      "management_text": "The effectiveness of chloramphenicol should be monitored, and plasma levels should be checked as clinically appropriate. Dosage should be increased as needed. The patient also should be monitored for barbiturate toxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39766,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39767,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Moderate",
      "effect": "Coadministration with strong inducers of CYP450 2C8 or CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of hydroxychloroquine. When rifampin, a CYP450 2C8 and CYP450 3A4 strong inducer, was administered concomitantly with hydroxychloroquine, a lack of efficacy of hydroxychloroquine was reported. Because hydroxychloroquine and chloroquine and have similar structures and metabolic elimination pathways, a similar interaction could be observed for chloroquine.Chloroquine or hydroxychloroquine may lower the convulsive threshold, which may antagonize the action of antiepileptic medications. Seizures have been rarely reported in patients on chloroquine or hydroxychloroquine therapy. The mechanism is unknown.",
      "management_text": "Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a strong CYP450 3A4 or 2C8 inducer. Clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 or 2C8 inducer is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. The potential risks and benefits should be evaluated prior to initiating chloroquine or hydroxychloroquine in patients on anticonvulsant therapy. In addition, patients with a history of epilepsy should be advised about the risk of chloroquine/hydroxychloroquine-induced seizures. Alternative anti-malarial agents may be required. Local treatment guidelines should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39769,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorothiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39770,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorphenesin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39771,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39772,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorzoxazone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39773,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Moderate",
      "effect": "Barbiturates may increase the plasma clearance of clonazepam and thereby reduce its clinical effectiveness. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Also, clonazepam may increase the effectiveness of barbiturates. A case of respiratory depression and coma has been reported in a patient receiving high doses of both clonazepam and amobarbital.",
      "management_text": "If these drugs are used together, close observation for altered clonazepam and barbiturate effects is indicated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39775,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39776,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39777,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39784,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease serum cyclosporine concentrations and efficacy. The mechanism is enhanced hepatic microsomal metabolism of cyclosporine.",
      "management_text": "Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when a barbiturate is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39785,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dextromethorphan",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39793,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39795,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diazoxide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39796,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dihydroergotamine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.",
      "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39799,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of diltiazem, which is primarily metabolized by the isoenzyme.",
      "management_text": "Use of diltiazem with rifampin or any known CYP450 3A4 inducer should be avoided when possible, and alternative therapy considered. Diltiazem dose adjustment should be guided by clinical response if concomitant use with a CYP450 3A4 inducer is necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39800,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39801,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39803,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39804,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dronabinol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39805,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Moderate",
      "effect": "Theoretically, potent CYP450 3A4 inducers may decrease serum concentrations of butyrophenones such as benperidol or droperidol. This interaction has been reported for haloperidol. However, clinical data are lacking for benperidol or droperidol. In addition, butyrophenones may lower the seizure threshold. Central nervous system- and/or respiratory-depressant effects may also be additively or synergistically increased in patients taking droperidol or benperidol with certain other drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "The potential for diminished neuroleptic effects of droperidol or benperidol should be considered during coadministration with potent CYP450 3A4 inducers. Pharmacologic response to these medications should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the droperidol or benperidol dosage adjusted as necessary. Patients taking potent CYP450 3A4 inducers that are anticonvulsants should be monitored for loss of seizure control. Additionally, when droperidol or benperidol are used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience seizures or excessive CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39806,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39811,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ergotamine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.",
      "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39817,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Esmolol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39818,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ethchlorvynol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39823,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ethosuximide",
      "severity": "Moderate",
      "effect": "The concomitant use of methsuximide and phenobarbital levels may result in increase serum levels of both drugs. The proposed mechanism is competition for the same metabolic pathway. Other succimides may also interact.",
      "management_text": "If phenobarbital and a succinimide must be used together, monitoring of serum levels and observation for evidence of altered efficacy and safety is recommended. Dose adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39824,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ethotoin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39825,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Moderate",
      "effect": "Some anticonvulsants such as carbamazepine, phenobarbital, phenytoin, and primidone may reduce the systemic exposure of etoposide. The proposed mechanism is accelerated clearance of etoposide due to induction of hepatic CYP450 enzymes by these anticonvulsants.",
      "management_text": "During concomitant therapy with certain anticonvulsants, patients should be observed for potentially inadequate or altered response to etoposide, and the dosage adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39827,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Moderate",
      "effect": ". The mechanism may be CYP450 enzyme induction by the anticonvulsants. Loss of antihypertensive efficacy may occur.",
      "management_text": "Blood pressure should be monitored during concurrent administration. Dosage adjustments may be necessary. Alternative antihypertensives (e.g., amlodipine) may be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39831,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39833,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.",
      "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39834,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39835,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Moderate",
      "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.",
      "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39836,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39837,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39840,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Griseofulvin",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease serum griseofulvin levels. The mechanism may be related to decreased absorption of griseofulvin. Therapeutic failure has been reported. Phenobarbital and primidone are the only barbiturates specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion.",
      "management_text": "Patients should be monitored for reduced antifungal efficacy. It may be necessary to increase griseofulvin doses or use alternative therapeutic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39842,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Guanethidine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39843,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39845,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydroflumethiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39849,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39855,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39860,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39861,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Moderate",
      "effect": "The concomitant administration of potent CYP450 3A4 inducers may significantly reduce itraconazole and ketoconazole serum levels. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of the antifungal agents. Antifungal therapy may fail.",
      "management_text": "Coadministration of potent CYP450 3A4 inducers with itraconazole or ketoconazole should be avoided. Some authorities recommend avoiding concomitant therapy with potent CYP450 3A4 inducers from 2 weeks before and during treatment with itraconazole. Fluconazole is eliminated unchanged by the kidneys and may be a more appropriate antifungal agent, depending on the patient's condition.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39864,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Moderate",
      "effect": "Barbiturates may induce or inhibit the metabolism of phenytoin. Plasma phenytoin concentrations may be decreased or increased. The mechanism are induction of hepatic CYP450 phenytoin metabolism by therapeutic doses of barbiturates, and competitive inhibition of metabolism by large doses.",
      "management_text": "Close laboratory and clinical observation for altered effects of both agents is recommended when doses of either agent are started, changed, or discontinued. Patients should be advised to notify their physician if they experience loss of seizure control or excessive or prolonged sedative effects. It may be necessary to alter the dosage of one or both of the drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39952,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pimozide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39953,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Prazosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39958,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39959,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.",
      "management_text": "Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39960,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Primidone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39963,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Procarbazine",
      "severity": "Moderate",
      "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.",
      "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39964,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Progesterone",
      "severity": "Moderate",
      "effect": "RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.",
      "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39965,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39966,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pyridoxine",
      "severity": "Moderate",
      "effect": "Large doses of pyridoxine (greater than 200 mg/day) may decrease the concentration of certain antiepileptic medications, including phenytoin and phenobarbital. The mechanism of this interaction is not known.",
      "management_text": "If large doses of pyridoxine must be used concomitantly with these medications, close observation for evidence of altered anticonvulsant effect is recommended. Patients should be advised to notify their caregiver if they experience loss of seizure control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39968,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Moderate",
      "effect": "Some barbiturates may significantly decrease serum quinidine concentrations and half-life. The mechanism is induction of CYP450 3A4 hepatic metabolism of quinidine. Data are available for pentobarbital, phenobarbital, and primidone.",
      "management_text": "Monitor the effectiveness and serum levels of quinidine until a stable, safe, and therapeutic level is achieved after a barbiturate is added or deleted from this patient's regimen. Dose adjustments may be required. Patients should be advised to notify their physician if they experience worsening irregular heartbeats or exacerbation of other symptoms. Patients should also be observed for quinidine toxicity after the barbiturate is discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39973,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Quinine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 including phenobarbital may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme. The extent to which other, less potent inducers of CYP450 3A4 may interact with quinine is unknown. Coadministration with quinine may increase the serum concentrations of phenobarbital. The mechanism of interaction has not been described.",
      "management_text": "The possibility of treatment failure should be considered if quinine must be used in combination with phenobarbital. Patients receiving quinine for malaria should be closely monitored. In addition, serum phenobarbital levels and pharmacologic response should be monitored during and after treatment with quinine, and the phenobarbital dosage adjusted as necessary. Patients should be advised to contact their physician if they experience potential signs and symptoms of phenobarbital toxicity such as sedation, hypotension, nystagmus, ataxia, and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39974,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39975,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Secobarbital",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39986,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Moderate",
      "effect": "Coadministration of carbamazepine with sertraline may result in a reduction in the plasma concentrations and therapeutic effects of sertraline. The proposed mechanism is carbamazepine induction of CYP450 3A4-mediated metabolism of sertraline. It cannot be excluded that other CYP450 3A4 inducers (e.g., phenytoin, phenobarbital (phenobarbitone), rifampin, St. John's wort) may also cause a reduction of sertraline plasma levels. In addition, it is possible that central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking carbamazepine and sertraline, especially in elderly or debilitated patients.",
      "management_text": "The potential for diminished therapeutic effects of sertraline should be considered when prescribed in combination with carbamazepine. Patients should be closely monitored, and the dosage of sertraline adjusted as necessary. Data are not available to guide dosing of sertraline when coadministered with potent CYP450 3A4 inducers. Alternative agents with no or minimal CYP450 3A4-inducing activity may also be considered. In addition, during concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39989,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39997,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39998,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tamoxifen",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.",
      "management_text": "In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40004,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40010,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Terazosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40012,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Theophylline",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.",
      "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40013,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Thiethylperazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40014,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Thiopental",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40015,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tranylcypromine",
      "severity": "Moderate",
      "effect": "Limited clinical data suggest that nonselective monoamine oxidase inhibitors (MAOIs) may enhance or prolong the central nervous system effects of barbiturates. The mechanism of interaction is unknown, but may involve inhibition of barbiturate metabolism by MAOIs. Somnolence, dizziness, ataxia, and semi-consciousness have been reported.",
      "management_text": "Until more information is available, patients should be monitored for increased barbiturate effects during coadministration with an MAOI or other agents that possess MAOI activity such as furazolidone, linezolid, methylene blue, and procarbazine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40024,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40025,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Triamterene",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40026,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40027,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40028,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trihexyphenidyl",
      "severity": "Moderate",
      "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol. These agents individually can cause cognitive and psychomotor impairment, drowsiness, and dizziness, thus concomitant use may result in more potent effects. In addition, the potential for abuse may be increased when central anticholinergic agents are combined with these drugs.",
      "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40029,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trimethadione",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40031,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trimethaphan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40032,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trimethobenzamide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40033,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trimethoprim",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 2C9 and 3A4 may decrease the plasma concentrations of sulfamethoxazole and trimethoprim. A small amount of sulfamethoxazole is metabolized by CYP450 2C9, while trimethoprim is partially metabolized by both CYP450 2C9 and 3A4.",
      "management_text": "The potential for diminished pharmacologic effects of sulfamethoxazole-trimethoprim should be considered during coadministration with potent CYP450 2C9 ad 3A4 inducers, particularly when sulfamethoxazole-trimethoprim is used for prevention of toxoplasmic encephalitis in HIV patients because adequate drug levels are required in the central nervous system. It may be advisable to refrain from low-dose prophylactic regimens (less than 4 DS tablets per week). Alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40034,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tripelennamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40035,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Moderate",
      "effect": "Valproate may increase the plasma levels of phenobarbital. The proposed mechanism may involve valproate inhibition of CYP450-mediated metabolism of the barbiturate. Central nervous system- and/or respiratory-depressant effects may also be additively or synergistically increased in patients taking valproate and phenobarbital concomitantly, especially in elderly or debilitated patients.",
      "management_text": "Patients started on combination therapy should be closely monitored for clinical and laboratory evidence of phenobarbital toxicity. They should be advised to notify their doctor if they experience excessive sedation or lethargy. Reductions in the phenobarbital dosage may be required; some authorities recommend reducing the phenobarbital dose by one-third to one-half when administered with valproate. Monitoring of the plasma concentrations of both drugs when starting, stopping, or changing the dose of either drug is recommended. During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40040,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Moderate",
      "effect": "Some barbiturates may significantly decrease serum verapamil concentrations and half-life, especially with oral dosage forms. The mechanism is induction of CYP450 3A4 first-pass metabolism of verapamil.",
      "management_text": "Close observation for reduced verapamil effect is recommended if these drugs must be used together. Dose adjustments may be required. Patients should also be monitored for verapamil toxicity after the barbiturate is discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40043,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vinblastine",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.",
      "management_text": "The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John's wort should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40044,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.",
      "management_text": "The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John's wort should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40045,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers may decrease the plasma concentrations of zolpidem, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2.",
      "management_text": "The potential for diminished pharmacologic effects of zolpidem should be considered during coadministration with CYP450 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John's wort. Alternative treatments or a dosage adjustment for zolpidem may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40051,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Benzatropine",
      "severity": "Moderate",
      "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol. These agents individually can cause cognitive and psychomotor impairment, drowsiness, and dizziness, thus concomitant use may result in more potent effects. In addition, the potential for abuse may be increased when central anticholinergic agents are combined with these drugs.",
      "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41671,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Betaxolol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 42617,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45109,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Brimonidine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.",
      "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 48589,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Butalbital",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52155,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Calcifediol",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin D analogs. These agents are thought to induce the hepatic conversion of vitamin D to inactive metabolites and have been shown to reduce circulating levels of active vitamin D, sometimes accompanied by reduced serum calcium and increased parathyroid hormone levels. Patients on long-term anticonvulsant therapy have occasionally developed osteomalacia, presumably due to interference with vitamin D and calcium metabolism. There have also been isolated reports of patients who responded poorly to vitamin D supplements during treatment with phenytoin and/or primidone.",
      "management_text": "Patients receiving vitamin D analogs with CYP450 inducers should be monitored for potentially reduced vitamin D effects. Dosage adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53684,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin D analogs. These agents are thought to induce the hepatic conversion of vitamin D to inactive metabolites and have been shown to reduce circulating levels of active vitamin D, sometimes accompanied by reduced serum calcium and increased parathyroid hormone levels. Patients on long-term anticonvulsant therapy have occasionally developed osteomalacia, presumably due to interference with vitamin D and calcium metabolism. There have also been isolated reports of patients who responded poorly to vitamin D supplements during treatment with phenytoin and/or primidone.",
      "management_text": "Patients receiving vitamin D analogs with CYP450 inducers should be monitored for potentially reduced vitamin D effects. Dosage adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53779,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Entacapone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57049,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Carbinoxamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57217,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Carmustine",
      "severity": "Moderate",
      "effect": "Coadministration of carmustine with phenobarbital can increase the metabolism of carmustine, which may weaken its antitumor activity. The mechanism of interaction has not been established; however, it appears to involve induction of hepatic enzymes.",
      "management_text": "Pharmacologic response to carmustine should be monitored more closely whenever phenobarbital is added to or withdrawn from therapy, and the dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 59156,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Moderate",
      "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.",
      "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 59900,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67104,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clemastine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 68307,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69731,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 72519,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cocaine (topical)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73208,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Colesevelam",
      "severity": "Moderate",
      "effect": "INTERVAL: Colesevelam may decrease the gastrointestinal absorption of coadministered drugs. Approximately 20% to 40% reductions in systemic exposure (AUC) and 10% to 45% reductions in peak plasma concentration (Cmax) have been reported for cyclosporine, ethinyl estradiol, glimepiride, glyburide, levothyroxine, olmesartan, and sustained-release verapamil during coadministration with colesevelam.",
      "management_text": "In general, drugs with a narrow therapeutic index as well as those that have been shown to interact with colesevelam should be administered at least 4 hours before the colesevelam dose. Clinical and laboratory monitoring of drug levels and effects should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73582,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74085,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of darifenacin, which has been shown to be a substrate of the isoenzyme.",
      "management_text": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 79502,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 83619,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dexmedetomidine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84981,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87615,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Moderate",
      "effect": "Barbiturates may decrease the serum concentration of disopyramide resulting in reduced antiarrhythmic efficacy and increased anticholinergic side effects. The mechanism may be induction of the CYP450 3A4 metabolism of disopyramide. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates are also enzyme inducers and may behave in a similar fashion.",
      "management_text": "Close observation for clinical and laboratory evidence of altered disopyramide effect is indicated. Patients should be advised to notify their physician if they experience lightheadedness, syncope, palpitations, irregular heartbeats, chest pain, dry mouth, or urinary retention.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 88860,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of the CYP450 3A4 and/or 2D6 enzymatic pathways may decrease the plasma concentrations of donepezil. The mechanism is accelerated clearance of donepezil due to enhanced CYP450 activities.",
      "management_text": "While clinical data are lacking, the possibility of a diminished therapeutic response to donepezil should be considered in patients receiving concomitant inducer agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 90361,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91285,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Doxylamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92182,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 93828,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 94303,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "Coadministration of phenobarbital and efavirenz may affect the plasma concentrations of both drugs. Theoretically, efavirenz levels may decrease due to induction of the CYP450 3A4 and 2B6 enzymatic pathways by phenobarbital, whereas phenobarbital levels may increase or decrease according to the product labeling for efavirenz. Pharmacokinetic data are not currently available. Phenobarbital is a substrate of CYP450 2C19 and 2C9, both of which are inhibited by efavirenz. However, the extent to which inhibition of these pathways may affect the overall clearance of phenobarbital is unknown. On the other hand, convulsions have been observed during efavirenz therapy, generally in patients with a known medical history of seizures. This would suggest a possible induction by efavirenz, a known inducer of CYP450 3A4 and possibly other hepatic microsomal enzymes, of the clearance of certain anticonvulsants that are primarily metabolized by the liver such as phenobarbital.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if efavirenz is prescribed in combination with phenobarbital or primidone, the latter of which is partially metabolized in vivo to phenobarbital. Close clinical and laboratory monitoring of antiretroviral response is recommended, and the efavirenz dosage adjusted as necessary. Alternative treatment that do not affect efavirenz metabolism should be considered whenever possible. Pharmacologic effects and serum phenobarbital levels should also be monitored more closely following the addition, discontinuation or change of dosage of efavirenz. Patients should be advised to contact their physician if they experience loss of seizure control or increased side effects of phenobarbital such as drowsiness, confusion, hallucinations, restlessness, depression, ataxia, lethargy, nystagmus, and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96140,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pregabalin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 101679,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103474,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Proparacaine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105797,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ropinirole",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 109928,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 110440,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pindolol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 154620,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Pramipexole",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 156230,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Procyclidine",
      "severity": "Moderate",
      "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol. These agents individually can cause cognitive and psychomotor impairment, drowsiness, and dizziness, thus concomitant use may result in more potent effects. In addition, the potential for abuse may be increased when central anticholinergic agents are combined with these drugs.",
      "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 157554,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Moderate",
      "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.",
      "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158080,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Protriptyline",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158319,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 159027,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ramelteon",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.",
      "management_text": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John's wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 159379,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of repaglinide, which is metabolized by the isoenzyme in the intestine and liver.",
      "management_text": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, patients treated concomitantly with rifampin may require a higher dosage of repaglinide. Blood glucose should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy in patients stabilized on their existing antidiabetic regimen, and the repaglinide dosage adjusted as necessary. Patients should be advised to contact their physician if they experience loss of glycemic control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 160879,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 2C8 may decrease the plasma concentrations of rosiglitazone, which is primarily metabolized by the isoenzyme.",
      "management_text": "Because the antidiabetic effect of rosiglitazone is dose- and concentration-dependent, patients treated concomitantly with a CYP450 2C8 inducer may require a higher dosage of rosiglitazone. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of the CYP450 2C8 inducer, and the rosiglitazone dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162888,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vigabatrin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 163724,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of a diminished therapeutic response to sildenafil should be considered.",
      "management_text": "Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 165826,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sorafenib",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which is partially metabolized by the isoenzyme.",
      "management_text": "Concomitant use of sorafenib with potent CYP450 3A4 inducers should be avoided whenever possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166909,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tadalafil",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 168429,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 169504,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Teniposide",
      "severity": "Moderate",
      "effect": "Some anticonvulsants such as carbamazepine, phenobarbital, phenytoin, and primidone may reduce the systemic exposure of teniposide. The proposed mechanism is accelerated clearance of teniposide due to induction of hepatic CYP450 enzymes by these anticonvulsants.",
      "management_text": "During concomitant therapy with certain anticonvulsants, patients should be observed for potentially inadequate or altered response to teniposide, and the dosage adjusted accordingly as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170146,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Moderate",
      "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.",
      "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170784,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tiagabine",
      "severity": "Moderate",
      "effect": "Population pharmacokinetic studies indicate that tiagabine clearance is 60% greater in patients receiving concomitant phenobarbital with or without other enzyme inducing antiepileptic drugs (AEDs). The mechanism is thought to be induction of the CYP450 3A4 metabolism of tiagabine by phenobarbital.",
      "management_text": "Clinical and laboratory monitoring may be necessary if these medications are used together, especially if phenobarbital or primidone are started or stopped in a patient stabilized on tiagabine. Patients should be advised to notify their physician if they experience loss of seizure control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 171275,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Timolol",
      "severity": "Moderate",
      "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.",
      "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 171726,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tinidazole",
      "severity": "Moderate",
      "effect": "Coadministration with a barbiturate may significantly decrease the plasma concentrations and pharmacologic effects of nitroimidazoles. The proposed mechanism is barbiturate induction of nitroimidazole metabolism via hepatic microsomal enzymes.",
      "management_text": "Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure. Two- to threefold dosage increases are not uncommon. Pharmacologic response to metronidazole should be monitored and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 171814,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 171912,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Moderate",
      "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.",
      "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 172133,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Tolcapone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 172714,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173120,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trandolapril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173359,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Treprostinil",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 2C8 may decrease the plasma concentrations of treprostinil, which is primarily metabolized by the isoenzyme.",
      "management_text": "Pharmacologic response to treprostinil should be monitored more closely whenever a CYP450 2C8 inducer is added to or withdrawn from therapy, and the treprostinil dosage adjusted as necessary. Patients should be advised to notify their physician if they experience worsening of their condition.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173623,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Trimipramine",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174285,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Triprolidine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174402,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175835,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.",
      "management_text": "The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John's wort should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176221,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Zaleplon",
      "severity": "Moderate",
      "effect": "Some drugs that are strong inducers of hepatic CYP450 3A4 enzymes may decrease zaleplon plasma concentration and result in loss of efficacy. Zaleplon is partially metabolized by this metabolic isoenzyme.",
      "management_text": "Clinical monitoring of patient response and tolerance is recommended and zaleplon dosage adjustments may be required. An alternative hypnotic may be considered. Patients should be advised to notify their physician if they experience loss of efficacy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176880,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 177277,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Zonisamide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of zonisamide, which is primarily metabolized by the isoenzyme.",
      "management_text": "Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary. Patients should be advised to notify their physician if they experience loss of seizure control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 177602,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Eprosartan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178658,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ergocalciferol",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin D analogs. These agents are thought to induce the hepatic conversion of vitamin D to inactive metabolites and have been shown to reduce circulating levels of active vitamin D, sometimes accompanied by reduced serum calcium and increased parathyroid hormone levels. Patients on long-term anticonvulsant therapy have occasionally developed osteomalacia, presumably due to interference with vitamin D and calcium metabolism. There have also been isolated reports of patients who responded poorly to vitamin D supplements during treatment with phenytoin and/or primidone.",
      "management_text": "Patients receiving vitamin D analogs with CYP450 inducers should be monitored for potentially reduced vitamin D effects. Dosage adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178813,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib. If alternative treatment is unavailable and a potent inducer (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, St. John's wort) is to be used for more than a few days, an increase in the dosage of erlotinib should be considered as tolerated at 2-week intervals. Close clinical and laboratory monitoring for altered efficacy and safety, including renal and liver functions and serum electrolytes, is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179035,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Eszopiclone",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme.",
      "management_text": "Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 180259,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Etanercept",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 180359,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Exemestane",
      "severity": "Moderate",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the isoenzyme.",
      "management_text": "The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. However, it has also been suggested that suppression of estrogen levels is not affected by the interaction, thus dosage adjustment of exemestane is not required. The extent to which other, less potent CYP450 3A4 inducers may interact with exemestane is unknown. Caution is advised if they are used with exemestane.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181334,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Felbamate",
      "severity": "Moderate",
      "effect": "Felbamate may decrease the hepatic metabolism of phenobarbital. Phenobarbital toxicity may result. In addition, phenobarbital may induce felbamate metabolism resulting in decreased felbamate concentrations. It may take up to 1 month to reach steady state phenobarbital concentrations.",
      "management_text": "If this combination cannot be avoided, the phenobarbital dose may require a 25% reduction. Patients should be closely monitored for clinical response and phenobarbital toxicity (drowsiness, ataxia, lethargy) for at least one month after initiating concomitant therapy. Decreased phenobarbital doses may be required if felbamate is discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181809,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Flavoxate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182572,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183611,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184005,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184848,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme.",
      "management_text": "Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. In patients receiving potent inducers such as rifampin or phenytoin, gefitinib product labeling states that a dosage increase to 500 mg daily should be considered in the absence of severe adverse reactions, and additional dosage adjustments be made based on clinical response. Gefitinib dosage should be decreased accordingly if these agents are discontinued.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185124,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187208,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187265,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Tricyclic antidepressants may counteract the anticonvulsive effects of barbiturates by lowering the seizure threshold. Barbiturates may decrease the serum levels and effects of tricyclic antidepressants by induction of hepatic metabolism.",
      "management_text": "If the barbiturate is being taken for a seizure disorder, patients should be closely monitored for loss of seizure control. Dose adjustments may be required. Monitoring for clinical evidence of additive toxicity and for clinical and/or laboratory evidence of reduced antidepressant effect is also advisable.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188168,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188425,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Infliximab",
      "severity": "Moderate",
      "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.",
      "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188576,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188849,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dexbrompheniramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189670,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190055,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cyproheptadine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190314,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cinchocaine (topical)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190512,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sibutramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192598,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Azatadine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193140,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Caspofungin",
      "severity": "Moderate",
      "effect": "Coadministration with inducers or mixed inducer/inhibitors of certain metabolic pathways may produce clinically meaningful reductions in the plasma concentrations of caspofungin.",
      "management_text": "Caspofungin product labeling recommends that during coadministration with efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone or carbamazepine, an increase in the daily dosage to 70 mg (following the usual 70 mg loading dose) should be considered in patients who are not clinically responding.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193142,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dihydrotachysterol",
      "severity": "Moderate",
      "effect": "Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin D analogs. These agents are thought to induce the hepatic conversion of vitamin D to inactive metabolites and have been shown to reduce circulating levels of active vitamin D, sometimes accompanied by reduced serum calcium and increased parathyroid hormone levels. Patients on long-term anticonvulsant therapy have occasionally developed osteomalacia, presumably due to interference with vitamin D and calcium metabolism. There have also been isolated reports of patients who responded poorly to vitamin D supplements during treatment with phenytoin and/or primidone.",
      "management_text": "Patients receiving vitamin D analogs with CYP450 inducers should be monitored for potentially reduced vitamin D effects. Dosage adjustments may be necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193145,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Promazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193154,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Propiomazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193155,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193159,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Triflupromazine",
      "severity": "Moderate",
      "effect": "Concomitant use of phenothiazines with barbiturates may reduce the plasma concentrations and therapeutic effects of both agents. The mechanism is unclear but may relate to metabolic induction of CYP450 hepatic enzymes. In addition, coadministration of phenothiazines and barbiturates may lead to a reduction in seizure threshold and additive central nervous system (CNS) and respiratory depressant effects.",
      "management_text": "Administration of phenothiazines in patients receiving large doses of barbiturates is considered contraindicated by some authorities (US). If coadministration is required, caution as well as clinical and laboratory monitoring should be considered whenever either of these agents is added to or withdrawn from therapy. If chlorpromazine is coadministered with a barbiturate, the manufacturer of chlorpromazine recommends using 1/4 to 1/2 of the usual barbiturate dosage. Patients should be monitored for hypotension, loss of seizure control and the development of adverse effects including CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193161,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with phenytoin and/or other enzyme-inducing anticonvulsants may decrease the plasma concentrations of valdecoxib. The mechanism is induction of CYP450 2C9 and 3A4, the isoenzymes responsible for the metabolic clearance of valdecoxib.",
      "management_text": "Patients already stabilized on valdecoxib may experience loss of pain and inflammation control with the coadministration of phenytoin and/or other enzyme-inducing anticonvulsants such as carbamazepine, oxcarbazepine, phenobarbital, and primidone. Pharmacologic response to valdecoxib should be monitored more closely whenever these agents are added to or withdrawn from therapy, and the valdecoxib dosage adjusted as necessary. In addition, because valdecoxib is a moderate inhibitor of CYP450 2C9 and 2C19 and a weak inhibitor of 2D6 and 3A4, valdecoxib labeling recommends that routine monitoring for alteration of antiepileptic efficacy be performed when therapy with valdecoxib is either initiated or discontinued in patients receiving anticonvulsants.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193162,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Acrivastine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247924,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Moderate",
      "effect": "Coadministration with potent CYP450 3A4 and/or 2C9 inducers may decrease the plasma concentrations and therapeutic effects of bosentan.  The proposed mechanism is increased clearance of bosentan by induction of CYP450 3A4 and/or 2C9, the isoenzymes responsible for the metabolic clearance of bosentan.",
      "management_text": "Until more information is available, the possibility of a diminished therapeutic response to bosentan should be considered when it is coadministered with a potent CYP450 3A4 and/or 2C9 inducer.  Clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 and/or 2C9 inducer is added to or withdrawn from therapy, and the bosentan dosage adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247932,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Moderate",
      "effect": "Concomitant use of orally and rectally administered formulations of budesonide with inducers of CYP450 3A4 may decrease budesonide systemic as well as local exposure at the gut mucosa.  Budesonide undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4",
      "management_text": "The potential for diminished pharmacologic effects of orally and rectally administered budesonide should be considered during concomitant treatment with drugs that induce CYP450 3A4.  Alternative treatments or budesonide dose adjustments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247933,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 2C9 may decrease the plasma concentrations of celecoxib, which is primarily metabolized by the isoenzyme.",
      "management_text": "The potential for diminished pharmacologic effects of celecoxib should be considered during coadministration with CYP450 2C9 inducers.  Dose adjustments or alternative treatments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247938,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fenfluramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247952,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 291680,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cholestyramine",
      "severity": "Minor",
      "effect": "Cholestyramine may decrease the absorption of phenobarbital. The clinical significance is unknown. Phenobarbital should be administered at least one hour before or four to six hours after cholestyramine. Patients should be monitored for altered phenobarbital effects.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 64801,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dextroamphetamine",
      "severity": "Minor",
      "effect": "Amphetamines may delay the intestinal absorption of ethosuximide, phenobarbital, and phenytoin. The mechanism of interaction and clinical significance are unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 84717,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dexmethylphenidate",
      "severity": "Minor",
      "effect": "According to the manufacturer, methylphenidate may inhibit the metabolism of anticonvulsants including phenobarbital, phenytoin, and primidone. There have been only isolated case reports of phenytoin intoxication during coadministration with methylphenidate and none for the other anticonvulsants. Nevertheless, it may be appropriate to monitor the pharmacologic response to these anticonvulsants more closely whenever methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is added to or withdrawn from therapy, and the anticonvulsant dosage adjusted as necessary.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 85113,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Enfortumab vedotin",
      "severity": "Minor",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 99620,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Propafenone",
      "severity": "Minor",
      "effect": "Some barbiturates increase the hepatic metabolism of propafenone. Plasma levels and efficacy of propafenone may be decreased. Data are available for phenobarbital. Propafenone efficacy should be monitored during coadministration, and plasma propafenone levels should be checked as necessary. It may be necessary to increase propafenone dosage.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 157808,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Raltegravir",
      "severity": "Minor",
      "effect": "Coadministration with inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 may reduce the plasma concentrations of raltegravir, which is primarily metabolized by UGT1A1-mediated glucuronidation. The impact of other potent inducers of drug-metabolizing enzymes such as carbamazepine, phenytoin, and phenobarbital on UGT1A1 is unknown. Other, less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, dexamethasone, St. John's Wort, pioglitazone) may be used with the recommended dosage of raltegravir.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 159282,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rufinamide",
      "severity": "Minor",
      "effect": "Coadministration with certain antiepileptic agents (carbamazepine, phenobarbital, phenytoin, primidone, vigabatrin) has been shown to decrease the plasma concentrations of rufinamide. The mechanism of interaction is unknown, since the majority of rufinamide clearance is via a non-CYP450 pathway.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 163439,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Febuxostat",
      "severity": "Minor",
      "effect": "Potent inducers of UGT enzymes (e.g., rifampin, carbamazepine, phenobarbital, phenytoin, ritonavir) may increase the metabolism of febuxostat and decrease its therapeutic efficacy. Febuxostat undergoes extensive metabolism by both conjugation via UGT enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7, and oxidation via cytochrome P450 enzymes. The relative contribution of each isoenzyme and the clinical significance is unknown. Conversely, increased plasma levels of febuxostat may occur after a potent UGT inducer is discontinued.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 181640,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Polatuzumab vedotin",
      "severity": "Minor",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 188631,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Relugolix",
      "severity": "Minor",
      "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 193156,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Amphetamine",
      "severity": "Minor",
      "effect": "Amphetamines may delay the intestinal absorption of ethosuximide, phenobarbital, and phenytoin. The mechanism of interaction and clinical significance are unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 24426,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Benzphetamine",
      "severity": "Minor",
      "effect": "Amphetamines may delay the intestinal absorption of ethosuximide, phenobarbital, and phenytoin. The mechanism of interaction and clinical significance are unknown.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 41423,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Bexarotene",
      "severity": "Minor",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bexarotene. In vitro studies suggest that bexarotene is metabolized by CYP450 3A4. However, concomitant administration with multiple doses of ketoconazole, a potent CYP450 3A4 inhibitor, did not alter bexarotene plasma concentrations, which would imply that bexarotene elimination is not substantially dependent on CYP450 3A4 metabolism in vivo. The effects of concomitant CYP450 3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampin) on the pharmacokinetics of bexarotene have not been studied.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 43274,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Minor",
      "effect": "Phenobarbital toxicity has been reported in a patient following initiation of diclofenac. The mechanism and clinical significance of this possible interaction is unknown. If these two drugs must be coadministered, the patient should be observed closely for phenobarbital toxicity such as slowness, ataxia, nystagmus, reduced reflexes and coma. Phenobarbital serum concentrations may need to be more closely monitored.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 54097,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Minor",
      "effect": "Coadministration with a barbiturate may decrease the plasma concentrations of carbamazepine and increase concentrations of its active 10,11-epoxide metabolite. The mechanism is barbiturate induction of CYP450 3A4, the isoenzyme responsible for the metabolism of carbamazepine to carbamazepine-10,11-epoxide (CBZ-E). Until more data are available, it may be reasonable to monitor serum carbamazepine levels more closely whenever a barbiturate (if used for more than a few days) is added to or withdrawn from therapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 56553,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cevimeline",
      "severity": "Minor",
      "effect": "Coadministration with inducers of CYP450 3A4 may theoretically decrease the plasma concentrations of cevimeline, which is a substrate of the isoenzyme. However, the clinical relevance has not been established, since cevimeline is also metabolized by CYP450 2D6, which is not inducible to any significant extent.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 61951,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Minor",
      "effect": "Barbiturates may slightly reduce the bioavailability of cimetidine. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 65713,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Minor",
      "effect": "Phenobarbital may enhance the metabolism of cyclophosphamide (and its metabolites) by increasing the rate of biotransformation of cyclophosphamide to its active metabolites. The clinical significance of this interaction appears to be minimal.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 76789,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dapsone (topical)",
      "severity": "Minor",
      "effect": "Theoretically, coadministration of dapsone with inducers of CYP450 3A4 such as rifamycins, anticonvulsants, barbiturates, and St. John's wort may increase the formation of dapsone hydroxylamine, a metabolite associated with hemolysis. Dose-related hemolysis is the most common adverse event associated with oral dapsone in both patients with or without glucose-6-phosphate dehydrogenase (G6PD) deficiency.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 79203,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Minor",
      "effect": "Dofetilide is metabolized to a small extent by CYP450 3A4 microsomal enzymes in the liver. The clinician should be aware of the potential for an interaction when dofetilide is used in combination with another medication that induces CYP450 3A4.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 89800,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Rifampicin",
      "severity": "Minor",
      "effect": "Rifampin may decrease the plasma concentrations of barbiturates by inducing hepatic metabolism. When given concomitantly with rifampin, patients should be monitored for inadequate response to barbiturates or decreases in serum concentrations, with dosages adjusted as necessary.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 161495,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Minor",
      "effect": "Phenobarbital may slightly increase biliary excretion of sulfasalazine. It has been suggested, however, that no special precautions are necessary when these drugs are coadministered.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 167655,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Ticlopidine",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 2C19 may theoretically increase the plasma concentrations of phenobarbital, which is a substrate of the isoenzyme. No precautions appear to be necessary during coadministration of phenobarbital with CYP450 2C19 inhibitors. However, dosage adjustments may be necessary if an interaction is suspected.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 171502,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Minor",
      "effect": "The effect of coadministration of topiramate with either phenobarbital or primidone has not been fully evaluated. The coadministration of topiramate with other antiepileptic drugs, such as phenytoin, valproic acid and carbamazepine has led to alterations in plasma concentrations of one or both drugs. Use caution if phenobarbital or primidone are coadministered with topiramate, and adjust dosages if needed.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 172874,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Eplerenone",
      "severity": "Minor",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of eplerenone, which is metabolized by the isoenzyme.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 178498,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Esomeprazole",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 2C19 may theoretically increase the plasma concentrations of phenobarbital, which is a substrate of the isoenzyme. No precautions appear to be necessary during coadministration of phenobarbital with CYP450 2C19 inhibitors. However, dosage adjustments may be necessary if an interaction is suspected.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 179709,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Minor",
      "effect": "Barbiturates may increase the hepatic metabolism of fenoprofen. Serum levels and effects of fenoprofen may therefore be reduced.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 182153,
      "ingredient1": "phenobarbital"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Minor",
      "effect": "Coadministration with inhibitors of CYP450 2C19 may theoretically increase the plasma concentrations of phenobarbital, which is a substrate of the isoenzyme. No precautions appear to be necessary during coadministration of phenobarbital with CYP450 2C19 inhibitors. However, dosage adjustments may be necessary if an interaction is suspected.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 183050,
      "ingredient1": "phenobarbital"
    }
  ]
}